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Advances in Reproduction
The Department of Obstetrics and Gynecology is
honored to have been asked to develop the 43rd
Annual McGuire Lectures. We were especially
pleased that this meeting coincided with the Annual
Meeting of the H. Hudnall Ware, Jr. Society which
is composed of the former residents of our Department of Obstetrics and Gynecology.
The purpose of the program was to summarize
major areas of recent advances in the field of reproduction. This intellectual time capsule could serve
us well as a point of reference by which we may
measure past and future progress. We chose as our
speakers and panelists those persons who could
speak with unquestioned authority in each specific
field . We are grateful to the participants, especially
Dr. Allan C. Barnes, our McGuire Lecturer, for
assembling in Richmond to honor the memory of
Dr. McGuire.
This issue of the MEDICAL COLLEGE OF VIRGINIA
QUARTERLY includes most of the lectures given at
the symposium. The two McGuire Lectures have
been summarized by the editorial staff, as Dr. Barnes
did not wish to have them published in their entirety.
LEO J. DUNN, M .D.

Chairman, Department of Obstetrics and Gynecology
Medical College of Virginia
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Current Knowledge of Gonadotrophin
Releasing Factor(s)*
EMANUEL M. BOGDANOVE, Ph.D.
Professor of Physiology,
Medical College of Virginia, Richmond, Virginia

In discussing the subject of gonadotrophin releasing factor(s) I cannot help but feel that for once
in my life I am really in tune with the times, since
the same subject was recently given a lengthy and
serious airing on a popular morning television program and has also been mentioned in the lay press.
It seems safe to predict that practitioners of gynecological medicine will soon be asked, possibly
even deluged with demands, to explain the significance of the releasing factor(s) to their patients.
I am not sure that what I am going to say here will
be exactly what these patients should be told, or
what they will want to hear, but I think it should
form the basis for a frank representation of the facts.
What I want to discuss are not the potential
therapeutic or diagnostic uses of these newly available compounds, which are really very speculative,
but certain features of the physiological control
system in which these compounds are thought to
play key roles. Any rational system of therapeutics
or prophylaxis involving these releasing factors, or
their derivatives, must be based on an adequate
understanding of ( 1) the physiological roles of these
compounds, (2) how these roles may be altered by
disease, and (3) the effects specific disturbances of
the control system ( s) in which they operate can be
expected to have on reproductive processes.
I will not review the background for my
remarks in detail, since I have recently done that
elsewhere (Bogdanove, 1972). The relevant literature is quite extensive but efforts to synthesize
meaningful interpretations of it have not been
lacking. There are several recent or imminent review articles,t and even an entire book (Meites,

* Presented at the 43rd Annual McGuire Lecture
Series, December 2, 1971, at the Medical College of Virginia, Richmond.
MCV QUARTERLY 8(1) : 5-12, 1972

1970), which would be particularly helpful as keys
to this literature.
It is generally accepted today that many if not
all of the secretory functions of the anterior pituitary gland are controlled, at least to some extent,
by the central nervous system. The vascular link
between the brain and the pituitary, the hypothalamic-pituitary portal system of veins, is viewed as
the final common pathway of neural control. The
idea that the neural influences are mediated by
"neurohumors,"t transmitted to the gland by these
portal veins, was first suggested by Friedgood
(Friedgood, 1936) and later placed on a solid experimental footing by G. W. Harris and his associates
(Harris, 1948; Harris, 1955; Harris and Campbell,
1966).
A large body of experimental evidence
indicates that the pituitary gland secretes little or
no LH and FSH if it is deprived of contact with the
hypothalamus, but that the injection of hypothalamic extracts can cause these two hormones to be
secreted. Similar partial or complete dependence
upon hypothalamic "neurohumoral" support is characteristic of the secretion of TSH, growth hormone,
and ACTH. However, the hypothalamic influence
upon the secretion of prolactin has been asserted to
be inhibitory, rather than stimulatory, since the
isolated pituitary secretes a lot of prolactin and
treatment with hypothalamic extracts can suppress
this hypersecretion.
t McCann and Porter, 1969; Burgus and Guillemin,
1970; Schally and Kastin , 1970; Gay, 1972; Saffran, 1972;
Schally, Kastin, and Arimura, 1972.
t Although these compounds do originate in the nervous
system, there is no evidence that they are secreted by
neurons. The possibility that they may be secreted by
glial elements (Knigge and Scott, 1970) cannot be overlooked.
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The active component(s) of the crude hypothalamic extracts have been frustratingly elusive, so
much so that some investigators (Schreiber, 1967)
have occasionally wavered in their faith that they
would eventually be isolated. Those who held the
faith, however, (as well as the rest of us) have been
rewarded by the recent isolation and identification
of several of the releasing factors* and the consequent preparation of pure molecules by organic
synthesis.
The two releasing factors which now appear to
be important for reproduction are TRH and GnRH.
It is the identifications of these two molecules which
have been hailed (quite rightly) as achievements
worthy of the attention of the news and propaganda media. It is on these two compounds, about
which the lay public (ever ready to plumb the mysteries of sex) will soon be demanding information,
that my remarks will focus.
The term "releasing factor" (RF) was coined
by McCann (McCann, Taleisnik, and Friedman,
1960) to signify the effect such a compound could
exert on the cells of the anterior pituitary glandcausing them to release a portion of their hormonal
content. Over the past 10 years, this term-RFhas largely supplanted the earlier name for this
group of neurohumoral factors-"hypophysiotrophins" or "hypophysiotrophic agents" (Guillemin
and Rosenberg, 1955)-which had a broader denotation. The physiological process involved in hormone secretion can be considered to have two
principal phases: synthesis (or production) of the
hormone and release of the hormone into the circulation (Gay and Bogdanove, 1968). In the case
of several of the hormones produced by the adenohypophysis, both phases of the secretory process
depend upon the integrity of the hypothalamicpituitary unit. If either the hypothalamus or the
vascular connection between the hypothalamus and
the anterior pituitary lobe is damaged, both release
and synthesis of the pituitary hormones are impaired (Bogdanove, 1972). Under acute experimental conditions, it is much easier to determine
whether something has stimulated release of a hormone than whether the processes of hormone synthesis have been influenced.
Figure 1 diagrams the relationship of the rates
of synthesis and release to the amount of hormone
stored in the gland (compartment I), as well as the
relation between the rate of release from the pitui*Nair, et al, 1970; Burgus, Dunn, et al, 1969; Baba,
et al, 1971.

tary and the levels of the hormone in the circulation. These levels, or titers, are the result of input
and output rates. When hormone enters the blood
faster than it leaves, titers increase; when the
entry rate is less than the exit rate, titers decline.
The concept is deceptively simple, however, since
the size of compartment II, which represents the
serum or plasma volume plus the summed volumes
of a series of extravascular compartments in equilibrium with the blood, is not known. Consequently,
it is not yet possible to establish the amount of
hormone which has to be added or removed to produce a given change in serum hormone concentration. Conversely, it is not yet possible to quantitate,
from measurement of changes in serum hormone
concentrations, the causative inequality between the
entry rate (rate of release of hormone from the
pituitary into the blood) and the exit rate (the combined rates of destruction and excretion of circulating hormone) during the time that serum hormone
titers were changing. One can merely infer that the
inequality existed. However, since exit rates from
the blood do not seem to vary as widely as rates
of entry into the blood, major changes in serum
hormone levels must reflect major changes in release rates.
Since the volume of compartment I can be
measured by simply weighing the pituitary (at
least in an experimental animal), it should be a very
simple matter to relate quantitative changes in intrapituitary hormone stores to transient inequalities
of synthesis (entry) and release (exit) rates. The
catch lies in establishing changes in intrapituitary
hormone stores, which poses a number of practical
problems. The foremost is that sampling of intrapituitary hormone levels requires removal of the
gland. This procedure, in contrast to blood sampling,
cannot be repeated. However, in theory at least,
any change in intrapituitary hormone content during
a finite period of time would have to represent the
product of that period of time and the algebraic
sum of the synthesis (entry) and release (exit)
rates.
Thus, release of a pituitary hormone can be
detected, if not measured, solely by observing an
increase in the concentration of the hormone in the
circulation. To establish a concomitant change in
hormone synthesis would be far more difficult. Since
our conceptions tend to reflect our fields of vision,
we tend to speak of "releasing factors" simply because effects on hormone release are more visible
than effects on hormone synthesis.
In using the pituitary as a model for illustrating
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If, in one of the compartments, a transient disequilibrium between A and C occurs, a change in B (stores or content) must result,
according to the relationship A - C = .:iB, where .:iB is the change in stores during the unit of time selected to express rate. BI can
be measured (as concentration X weight-content) and BII can be calculated from the concentration of the hormone in the plasma,
if the distribution volume is known (concentration X distribution volume = total circulating hormone). None of the rates (AI, CI,
All, Cllx, or Clla) has ever been measured. However, in a relatively steady state, as in a rat castrated 4 or more weeks previously
(where Clla = 0), .:iBI ~ .:iBll ~ 0 and therefore AI ~CI = All ~ Cllx.
In the "stop-entry" experiment (acute removal of compartment I by hypophysectomy) All instantaneously becomes zero but
CIIx, the rate of exit from the plasma, slows gradually. Although Cllx immediately starts to decrease, seemingly as an exponentia
function of BII, its instantaneous initial (zero time) value, which must about equal the steady state (pre-hypophysectomy) values of
AI, CI and All, can easily be calculated, as explained in the text. (Redrawn with permission from Gay and Bogdanove. Endocrinology
82:359, 1968.)

the input-output relationships involved in the processes of secretion, I have focused on the most
meaningful accessible index of activity-changes in
serum hormone concentration ( 6.BII in Fig. 1 ) . If
we wish to focus on hypothalamic secretory activity,
the problems become very much greater. Figure 2
illustrates a current concept of how the hypothalamus and pituitary are integrated with other organs
involved in the control of reproductive activity. The
evolution of this model has been reviewed elsewhere
(Bogdanove, 1972). For our present purpose, a discussion of current knowledge of gonadotrophin releasing factor ( s), this model is presented merely to
locate the subject of discussion.
As shown in Fig. 2, arrow 3 represents the
secretion of releasing factors, which act (either
alone or in conjunction with other internal environmental influences) to induce secretion of pituitary

gonadotrophic hormones (arrow 4). It is precisely
this stimulus-response relationship which has provided the existing operational definitions of the socalled releasing factors. Thus, a factor which released FSH was called FSH-RF (Igarashi and
McCann, 1964). One which released LH was called
LH-RF, or LRF (McCann, Taleisnik, and Friedman,
1960). A factor thought to affect FSH synthesis
(Corbin and Milmore, 1971 ) or prolactin synthesis
(Nicoll and Fiorindo, 1969) was given still another
name. One which decreased the rate of prolactin
release was dubbed PIF or PRIF, for prolactin release inhibiting factor. In every case, the definition
was indefinite-there was never any valid reason
for believing that LRF and FSH-RF were separate
entities (despite published conclusions to that effect
which will not be cited here) . As long as the changes
in pituitary hormone release rates which were ob-
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served-plus any changes which may also have occurred without being detected-had been induced
by administration of crude, or even partially purified,
hypothalamic extracts, it was simply impossible to
attribute the response ( s) to specific components of
the extracts. Thus, acid extracts of rat (or sheep,
or pig, or steer) hypothalamus could release TSH,
growth hormone, ACTH, LH, FSH, and, under
some conditions, MSH (melanophore-stimulating
hormone, or intermedin) . At the same time, they
could inhibit release of prolactin. The extent to
which these, and other, effects could be attributed
to the presence of specific hypophysiotrophic
molecules in these extracts still remains to be determined. Until all such demonstrations have been reproduced, using "RFs" of unequivocal purity, our
views of how the hypothalamus might exert its
effects on pituitary secretory activity will have to
remain indefinite.
This was the urgent reason for the intense and
sustained efforts of the several laboratories which
were engaged in the great releasing-factor hunt of
the last decade. The task of collecting and extracting hundreds of thousands of hypothalamic fragments from sows and cows and ewes, in order to
obtain, at the end of nearly 10 years, the smidgins
of purified materials needed to define the chemical

structures of the RFs, can truly be described as epic.
The results of these Augean labors have finally begun
to be visible. The structure of the thyrotrophin releasing hormone TRF (or TRH, using Schally's
nomenclaturet) was discovered barely a year before that of the single decapeptide molecule which
appears able to release both LH and FSH (Baba,
et al, 1971). The name of this molecule has not
yet been settled. Schally has given it the quasiacronym "LH-RH/FSH-RH," but the same molecule is being prepared synthetically, by Abbott
Laboratories, under the name of GnRH (for
gonadotrophin-releasing hormone).
Far more important than what this compound
should be called is the question of what it can do;
t Schally has proposed (Schally, Arimura, et al,
1968) that the RFs be called RHs (for releasing hormones) on the basis that they ought to be recognized
as full-fledged members of the community of hormones.
Guillemin and others (Burgus and Guillemin, 1970; Bogdanove, 1972) have objected to Schally's terminology, for
several reasons. Still other nomenclature has recently been
proposed (Saffran, 1972). Debate about etymological
propriety seems pointless since these compounds will be
known best by the names under which they are distributed
by the pharmaceutical companies which undertake to mass
produce them. Therefore, despite my previous objections, I
will refer to Schally's LH-RH/FSH-RH as GnRH.
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first for the physiologist and subsequently for either
the physician and his individual patient, or for the
public health and agricultural scientists who are
concerned with the control of human apd animal
fertility on a larger scale. I think the answers to
these questions are of vital importance, but I do
not think I or anyone can give them just yet.
We do not yet know whether GnRH is the only
factor secreted by the hypothalamus which can influence LH and FSH secretion. As a matter of fact,
we do not even know that GnRH is secreted by the
hypothalamus, but only that it can be extracted from
it. [The increased LH and FSH releasing activity
which can be shown in portal venous blood after
the hypothalamus has been stimulated (Kamberi,
et al, 1971) , may or may not be due to increased
GnRH concentration in that blood.] If GnRH is,
in fact, the only gonadotrophin-releasing factor, what
is its physiological role? Is it involved In disease?
·
How can we make use of it?
Much work lies ahead before these questions
will be answered. If we pause to think for a moment
about some of the major steps toward our present
understanding of the pituitary hormones involved in
reproduction, we may be able to glimpse some parallels in the problems which lie ahead in the study
of hypothalamic hormones.
The demise of the Aristotelian notion of pituitary function came about when pioneer surgeons and
physiologists (Crowe, et al, 1910; Smith, 1927)
removed the gland from the living animal and
discovered that the major resultant deficiencies
were not in the production of nasal mucus, but
in somatic growth (particularly at epiphyseal
plates) and the activities of what we have now cori:J.e
to know as the pituitary target glands: thyroid,
adrenal cortex, and gonads. (Similar deficiencies result from damage to the hypothalamus or isolation of
the pituitary from hypothalamic influence.) The
next steps were to show that injection of extracts
of anterior pituitary tissue could remedy these varc
ious deficiencies and that specific fractions of such
extracts could selectively restore specific functions.
It is through this substitutive approach that the existence of seven distinct adenohypophyseal hormones
was finally defined: LH, FSH, TSH, ACTH, prolactin, growth hormone, and MSH. It took a long
time to accomplish this partial goal, primarily because
it took so long to determine the actual structures
of the macromolecules secreted by the anterior
pituitary. (In this respect, the oligopeptidic hypothalamic hormones should present much less of an
obstacle.)

9

As sufficiently pure pituitary hormones became
available it was found that FSH alone could produce
follicular growth, but not estrogen secretion, in
hypophysectomized rats (Greep, 1968). If a little
LH was administered with the FSH, steroid secretion also resulted. Ovulation and formation of a
corpus luteum required a rapid surge of a large
amount of LH, superimposed on this "priming" of
the follicle by FSH and a trace of UJ. Physical
maintenance of the corpus luteum appeared to require nothing from the pituitary (corpora lutea survived for months in hypophysectomized rats) although secretion of luteal hormones did. In the rat
and mouse, but not in other animals, prolactin was
found to be luteotrophic, capable of activating the
secretory machinery of the corpus luteum. In the
male, FSH alone has been credited with a role in the
production and maintenance of spermatogenesis
(Steinberger, 1971 ), while LH is clearly capable qf
stimulating androgen production by the Leydig cells.
(The androgen, in turn, stimulates spermatogenesis.)
The male does not seem to use prolactin as a gonadotrophin, although he can use it as a lactogenic
hormone under certain conditions.
We are now entering a comparable phase of
substitutive investigation of the releasing factors. So
far, only two or three facts have emerged which
merit comment. One is that the response of the pituitary to GnRH can be influenced, at least quantitatively, by steroid feedback (long-loop arrow, probably to box IV, in Fig. 2), as well as by either
genetic sex or some consequence thereof. The evidence for this is that when identical doses of natural
porcine GnRH were injected into male and female
castrated rats which had been pretreated with ovarian
steroids or testosterone (four groups in all), the response in the spayed rats which had been pretreated
with ovarian steroids greatly exceeded that in the
similarly pretreated orchidectomized rats and in the
testosterone-pretreated , castrates of either sex
(Rennels, et al, 1971). Evidence that steroids can
act directly at the pituitary level to qualitatively
alter pituitary activity, presumably by modifying
the effects of either GnRH or some other hypophysiotrophic agent(s), has been presented recently (Kingsley and Bogdanove, 1971). These two
facts suggest, but do not establish, that it may not
be necessary to postulate neural participation in
every change in LH or FSH secretory rate, or every
shift in the LH:FSH ratio, which may occur under
physiological or experimental conditions. Thus, although changes in LH and FSH secretion may result from changes in GnRH secretion, it is also pos-
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sible that changes in the pituitary output of these
two hormones can occur without any precedent
change in hypothalamic secretory activity. For this
to happeq, it would be necessary for pituitary responsiveness to GnRH to vary under the influence
of one or several control agents other than GnRH. It
remains to be determined whether sex steroid feedback, which apparently can influence pituitary responsiveness to releasing factor ( s) under experimental conditions, can also do so under physiological
conditions.
Another fact is noteworthy. Both human
(Gual, et al, 1972) and rat (Tashjian, et al, 1971)
pituitary cells can be stimulated to release prolactin
by TRH! The mechanism of this unexpected finding remains to be established.
As additional synthetic releasing factors become
available, and additional clever or lucky experiments
are carried out, a considerable body of data will
develop. From it, the physiologist will venture, about
the secretion of endogenous releasing factors, opinions for which today there is not yet a sufficient
foundation . The aim of substitutive research must
be to supply the pituitary gland deprived of hypothalamic control with a sufficiently elaborate replacement for its natural releasing factor input (a
sort of prosthetic hypothalamus) , so that its behavior
will mimic that seen when neural controls are allowed
to operate. Even from such substitution studies, however, conclusions should be drawn with caution. The
caveat I would stress is that substitution studies reveal only what a hormone can do, not necessarily
what it does. As an example of the distinction, consider ihe impression-based on the demonstrable
proportionality between the amounts of FSH injected
and the resultant sizes of ovarian follicles-that the
progressive growth of the follicle during the preovulatory phase of the cycle reflects a progressive
increase in the rate of FSH secretion. This impression, derived from substitution studies, has not
been borne out by direct observation. Figure 3 shows
the patterns of LH and FSH in the serum during
the menstrual cycle in the human. Note that, during
the follicular phase of this cycle, serum FSH levels
do not increase, but actually seem to decline. This
finding would not have been anticipated on the basis
of substitution experiments.
Ultimately, it is always necessary to follow the
substitutive approach with an analytical one, aimed
at characterizing patterns of secretion by direct observation. However, I think it will be some time
before' direct analysis of releasing factor secretion
becomes a possibility. For most of the past 10 years,
'

Measured b
Ovarian Response

a.)

OVARY

b.)

LH or FSH Measured b RIA
PITUITARY

c.l

RF, Measured by RIA
)
(not yet possible)
'

Fig. 4- Components of RF assays : a. "Double" bioas~ay,
in which end-point is an ovarian response; b. "Single"
bioassay, in w)1ich end-point is a pituitary response determined by _radioimmunoassays (RIA) of serum; c. Direct
assay, .which does not involve any biological response.
(This trpe of assay is not yet available.)
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measurements of releasing factor activity have required a "double bioassay" (Fig. 4) in which the
effect of the factor on the pituitary (a biological
response) could be assessed only by bioassay (involving a second biological response) . The order of
error in such an assay system was usually, perhaps
always, sufficiently enormous that conclusions had to
be based on intuitive selection among several possibilities. The advent of radioimmunoassay methods
for measuring pituitary hormones very precisely has
reduced error by eliminating the second, but not the
first, biological response. I think at least some of
what has been reported on the basis of double bioassays will not bear careful scrutiny using single
bioassays.
Total elimination of a bioassay step, through
development of radioimmunoassays for releasing
factors, is of course desirable. However, some interesting calculations by Gay (Gay, 1972) are noteworthy. These calculations, based on substitution
studies, suggest that the concentrations of releasing
factor ( s) in the hypothalamic-pituitary portal circulation would have to be 2 to 3 orders of magnitude
below the limits of sensitivity of any known radioimmunoassay. In peripheral blood, they would be
lower still. When this is considered together with
the fact that there are no methods available for
sampling portal venous blood in an unanesthetized
animal, the chances for characterizing patterns of
spontaneous releasing factor secretion by direct observation still seem very remote.
If I have drawn too dismal a picture, I am
sorry. Schally's gift of GnRH is a great one, and a
beautiful scientific achievement. To the physiologist, it is a find comparable to the Rosetta stone,
without which the system depicted in Fig. 2 could
never be understood. To the physician, it may prove
to be a useful diagnostic tool and perhaps even,
ultimately, to have some therapeutic value. But its
primary value is that of the key to an unsolved
puzzle. While the key may now be at hand, the
solution ( s) to the puzzle must still be worked out.
"
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Artificial Insemination in the Human*
JOHN A BOARD, M.D.
Professor of Obstetrics and Gynecology,
Medical College of Virginia, Richmond, Virginia

The idea that impregnation might occur without coitus has aroused interest since ancient times.
In the second century AD., there was recorded
a hypothetical discussion concerning a woman who
had been inseminated by semen previously deposited in the bath water in which she bathed. In
1322, an Arab used artificial insemination with
horses. A wad of wool was introduced into the
vagina of a mare and left overnight. It was then
held over the nostrils of a stallion, and with this
stimulus the stallion ejaculated on a cloth held
in readiness. The ejaculated material was then
introduced into the vagina of a mare, which foaled
after the appropriate length of time.
During the 1700's, isolated instances of human artificial insemination were reported, almost
always using the husband's semen. In the United
States, human artificial insemination using donor's
semen was first practiced by Dr. Robert L Dickinson in 1890. His work was initially done in
secrecy, although subsequently he did much to
train others in the technique and to gain public
acceptance of the procedure.
Artificial Insemination Using Donor's Sperm.
The most common indication for artificial insemination using donor's semen is sterility of the husband. This may be manifest as total azoospermia
or severe oligospermia, demonstrated on repeated
examinations. The husband should, of course, have
a thorough medical and urologic examination to be
certain that his sterility is not secondary to a treatable condition. Considerable judgment is required
to decide when to treat cases of oligospermia this
way. In most instances, this is done when appropriate medical therapy has failed to improve
the quality of the ejaculate and artificial insemina-
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tion using the husband's semen has not resulted
in pregnancy.
When Rh incompatibility has already resulted
in the birth of an erythroblastotic infant, and particularly when the husband is homozygous Rh positive, insemination of the wife with semen from an
Rh negative donor will prevent the recurrence of
erythroblastosis. Fortunately, the availability of
Rho (D) immune globulin (human) has dramatically reduced the number of Rh negative women
who have been sensitized, and this is becoming
a less common indication for artificial insemination.
When the husband has a family history of
genetic disease which makes fatherhood inadvisable or when the couple has had affected offspring
indicating abnormal recessive genes with the likelihood of producing serious congenital defects in
subsequent pregnancies, artificial insemination with
donor's semen may be used. Examples of this are
Tay-Sachs disease, and cases where both husband
and wife have AS hemoglobin.
The presence of agglutinating antibodies
against the husband's sperm but not against donor
sperm may occur in a woman with prolonged and
otherwise unexplained infertility · (Dukes and
Franklin, 1968). The test for this is not an absolute
one, as some women who agglutinate their husband's
sperm have been of high fertility. In a situation
where antibodies are present, in some cases the
use of condom for a time to protect against repeated
exposure to antigen will result in disappearance of
agglutinating antibodies followed by pregnancy.
Where condom therapy fails, artificial insemination
using donor's sperm which are not agglutinated
by the wife's antibodies may be used. The ABO
relationship to infertility is even more unclear,
although there seems to be a statistically significant
effect when an ABO incompatibility exists and
the husband is a "secretor," in which case donor
semen from a male of appropriate blood type may
result in pregnancy.
13
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Donor insemination has special emotional
connotations, and both husband and wife should
be aware of the possible emotional effect of the
procedure on their future relationship. Both husband and wife should be reasonably well-adjusted
individuals, and they should feel that they have a
stable marriage. It is extremely important not to do
this procedure to "save the marriage" as this is
far too big a job to place upon the shoulders of an
individual who weighs only seven pounds or so.
Both husband and wife should have a desire for
children, and the man should not feel that he is
being coerced into this procedure in order to provide fulfillment of his wife's maternal instincts.
In most cases, it is advisable to wait for a while
after the husband has found out about his sterility
problem before carrying out artificial insemination
because he will need time to recover from the
shock that such news is to every man. When it has
been decided to use insemination with donor's semen, both husband and wife should sign a consent
form.
In the past when there was no shortage of
babies for adoption, we did not encourage artificial
insemination, but did it only when the couple
specifically requested it, feeling that adoption
solved two social problems, that is, providing a family to the child and a child to the family. With the
recent increase in therapeutic abortions, the supply
of infants for possible adoption has so dwindled
that artificial insemination is more often mentioned
to the couple as a solution to their infertility or
genetic problems. Aside from suggesting the availability of donor's semen to such couples, we do
not try to encourage this where either partner
expresses any hesitancy.
A fertility investigation is done for each couple
seeking artificial insemination, if this has not been
previously accomplished. As a minimum, patency
of the wife's fallopian tubes is established by a
Rubin's test using carbon dioxide, and an endometrial biopsy is done to confirm ovulation. The
patient is also instructed to begin keeping basal
temperature charts, in order that the most optimal
time for insemination may be selected. After reviewing temperature charts for several months, a
day is selected. This day will likely be one or two
days prior to the basal temperature rise. It has
been our practice to perform insemination once a
month for the first three months, and if pregnancy
has not occurred in this time, then to perform several at two-day intervals until the temperature rise
has definitely occurred. Some physicians use a rat
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ovary hyperemia test to predict the time of ovulation. This test is said to be capable of determining
the time of ovulation within six to twelve hours
(Farris, 1948). More recently, the use of rapid
radio immunoassay procedures for LH, in order to
detect the pre-ovulatory LH peak, has been suggested as an aid in timing the deposition of sperm,
whether it be by natural or artificial means.
Kleegman has found there is a sex differentiation in infants related to the time of artificial insemination and ovulation (Kleegman, 1967). She
utilized basal temperatures somewhat to determine
the time of ovulation, but put more emphasis on
mittelschmerz (sometimes elicited with a "bounce
test") and mucorrhea. Using this as evidence of
ovulation, she has noted that exposure 2-24 hours
before ovulation was more likely to result in a
male infant and that exposure 36 or more hours
before ovulation or 2-8 hours after ovulation was
more likely to result in a female infant. She was
able to predict sex in 77 % of cases utilizing this
method. She also noted that men who have severe
oligospermia but whose wives have still become
pregnant, have a preponderance of female children and that rhythm failures with conception occurring on cycle days 4 to 7 usually result in
female infants. Certain other investigators have been
unable to reduplicate this accuracy in prediction
(Cohen, 1966), but in fairness to Kleegman, it
should be noted that most have used only basal
temperature as an index of ovulation and have not
relied on mittelschmerz or cervical mucus changes.
Most of the donors which we use are either
medical students or house officers, who are married
and are already fathers of normal children. These
men report no knowledge of hereditary disease
and are of above average intelligence, If the wife
has Rh negative blood, an Rh negative donor is
also chosen. We do not make any effort to match
blood types otherwise, because any good laboratory
could readily establish the fact that the woman's
husband is not the father of the child by utilizing
other blood groups such as the MN, Kidd, Duffy,
and Kell which establish a "fingerprint." We make
an effort to match donor to husband by somatic
type, skin, hair, and eye coloration, but this is not
always possible. We would not, however, use a
short, black-haired donor of Mediterranean origin
for a couple where both husband and wife were tall,
blonde, and fair-skinned.
Our experience has been entirely with fresh
semen, and the donor is instructed to obtain a
specimen by masturbation into a clean glass con-
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tainer shortly before the couple's appointment. The
donor then delivers the semen to a designated
point, and it is then transferred to the patient area
by other personnel. It is important that the donor
not deliver the specimen himself to this office, in
order to exclude the possibility that he and the
recipients might meet. In order to preserye anonymity, the couple always pays the donor in cash.
Our practice is to keep no record of which donor
is used for insemination, and this precludes using
the sarne donor for subsequent pregnancies. It is
of note that some physicians do not even record
in the patient's chart the fact that insemination
was done.
On the selected day, the patient lies on an
examining table, and an unlubricated vaginal
speculum is inserted. The donor's semen is drawn
into a syringe which has a small length of polyethylene tubing attached to it. The husband then
comes to the examining room. The husband holds
the syringe and deposits 0.1 to 0.5 ml. of semen
about 1 cm. within the endocervical canal. The
polyethylene tubing and speculum are then removed, and a plastic cap with an attached · tubing
is placed over the cervix. The remainder of the
donor's semen is then inserted into the cervical
cap by the husband. We feel that this active participation in the insemination of the wife by the
husband is very important for him psychologically.
The cervical cap is sometimes difficult for the patient
to remove, so while the husband is in the examining
room, we instruct both him and his wife on the
removal of the cervical cap, and to date, between
the two of them, this has always been accomplished
at home.
We do not advocate the mixing of husband's
ejaculate with donor's semen or that the couple
have intercourse immedfately prior to coming to
the office for insemination. A cervical mucusspermatozoa incompatibility is not alway due to a
cervical factor, and one case was reported where
the donor's sperm but not the husband's sperm
readily entered the wife's cervical mucus (Kunitake and Davajan, 1970) . When the husband's
sperm was separated from the seminal plasma and
resuspended in seminal plasma from a donor
who had had a vasectomy, good penetration of
the wife's cervical mucus was obtained. Unless
this seminal plasma factor is checked for, it would
be inadvisable to mix husband's semen with donor's
semen. After the cervical cap has been · in place
for six hours or so, the couple is advised to remove
it, and it is suggested that they ~hen have intercourse.
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By this time, active sperm should be well on their
way up the female reproductive tract and any lethal
activity in the seminal plasma would be of no consequence.
When a woman has somewhat irregular ovulation, she is given an injection of 5000 international
units of human chorionic gonadotrophin to act as
µn LH surge, hopefully to cause an impending
ovulation to occur while viable sperm are still
present (Fuchs, et al, 1966).
··
The effectiveness of insemination using donor
semen has been shown in many studies. In an analysis of seven reported series which included 630
couples who had used artificial insemination with
donor semen, the proportion becoming pregnant
varied from 55-78 % . Of the women who' eventually
became pregnant, between 31 and 46% became
pregnant during the first month of inseminµtion. The
number of inseminations per menstrual 1"cycle appeared to be more significant in obtaining an early
pregnancy than the method of semen deposit
(Potter, 1958). About 90% of the women who
became pregnant did so in 6 months, and if a
pregnancy has not resulted within 12 months, the
chances of success are very remote.
·
Artificial Insemination Using Husband's Semen.
Indications for insemination using husband's semen
include failure to deposit the serrien in the posterior
vaginal fornix, inadequate cervical invasion, and a
moderate but irreversible degree of male infertility.
The failure to deposit the semen may be due
to penile or vaginal malformations, impotence, or
retrograde ejaculation. Penile hypospadias was one
of the first-recorded indications for artificial
inseminations, and this is still valid. The cases of
impotence are best individualized,. and decisions
should be made ·only after consultation with the
husband's psychiatrist. The the~apy for male
impotence · is psychiatric, · and in some instances a
pregnancy in the wife and impending ·fatherhood
will exert a beneficial psychiatric effect, while in
others this is best postponed until psychotherapy
has progressed further. Retrograde ejaculation may
follow injury to the internal bladder sphincter due
to surgery such as transurethral resection. However,
retrograde ejaculation may also be due to congenital anatomical abnormalities or neurologic
problems, including diabetes and chemical sympathectomy achieved with guanethidine. Typically,
there is not . only azoospermia but also markedly
reduced semen volume, although an ejaculatory
sensation is experienced with orgasm. To corroborate
the diagnosis, the patient empties his bladder and
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then ejaculates in one glass, after which he collects
in a separate glass whatever urine is in the bladder.
Artificial insemination using husband's semen
is also sometimes used in an attempt to bypass the
cervical mucus when it is found that normal sperm
cannot migrate through this or when postcoital tests
reveal no living sperm In the presence of apparently normal mucus and a good sperm count. The
achievement of pregnancy in these last two instances
is quite rare in our hands, although Kleegman
reported a success rate of around 85 % in the small
group where the only abnormal factor was a cervical secretion impenetrable to sperm (Kleegman
and Kaufman, 1966). She stated that most cases of
cervical impenetrability are due to endocrine dysfunction rather than cervicitis, and the results of
husband insemination in this group are poor. Others
have found consistently poor results in all attempts
to bypass the cervix (Balin, 1967).
When intrauterine insemination is done, the
cannula is placed in the endometrial cavity and
only 0.5 ml. or less of semen is instilled. This is
done very slowly with practically no pressuq:~. The
physician must be careful not to inject the
semen through the fallopian tubes into the peritoneal cavity where it will cause a peritonitis, and he
must be ready to stop the installation if the patient
complains of any cramping.
· Insemination with husband's semen may be
tried when the wife is of apparently good fertility
and the husband's sperm consistently has a low
count with the postcoital test showing only a few
sperm in the cervical canal. This may also be
utilized when the husband's sperm count is within
normal limits, but the motility of the sperm is less
than normal. The split ejaculate offers a concentrated
number of better sperm, and is often employed
when husband's semen is to be inseminated.
Split ejaculates are obtained simply by using
one clean container for the first part of the ejaculate and another for the remainder. It is most useful
when the volume of the ejaculate is over 2 ml.
In one study of 86 husband donors, the count was
significantly higher in the first portion than in the
second portion of the total specimen in 88%,
equally distributed in both in about 8 % , and
significantly higher in the second portion than in
the first in 6 % . Sperm motility was greater in the
first portion in 77%. In · 25 cases of increased
viscosity of the total ejaculate, the second portion
was consistently the most viscous ( Amelar and
Hotchkiss, 1965).
Biochemical studies of the split ejaculate have

BOARD: ARTIFICIAL INSEMINATION IN THE HUMAN

indicated that the first half contains the main bulk
of acid phosphatase, which comes from the prostate, along with the products of the testes, epididymis, and vas deferens . Since lactic acid accumulates as an end product of the metabolism
of spermatozoa, it is also found in greater concentration here. In the second half of the split
ejaculate, the higher · concentration of fructose is
found, a substance specific to the seminal vesicles
(Amelar and Hotchkiss, 1965; MacLeod and Hotchkiss, 1942).
Centrifugation of the full specimen concentrates the sperm, but frequently depresses the
motility and also concentrates the debris and mucus.
Concentration of the sperm can be obtained using
the split ejaculate without injuring the cells and
without concentrating debris also.
Kleegman reports that with 100 consecutive
women who had intrauterine insemination of the
split ejaculate in cases where there was subnormal
husband's sperm quality, 17 women )Jecame pregnant (Kleegman and Kaufman, 1966). Other reports include 15 % pregnancies in 86 women with
insemination of husband's semen (Kaskarelis and
Comninos, 1959). A number of women who failed
with insemination conceived subsequently with
normal intercourse.
Insemination with husband's sperm suspended
in donor's seminal plasma may be considered in the
rare cases where the husband's own seminal
plasma contributes to cervical mucus-spermatozoa
incompatibility or where there is excessively low
fructose in the husband's seminal plasma (Moon
and Bunge, 1968) .
Frozen Semen. Much has been written about
the practical applications of frozen human semen,
with the establishment of human semen banks.
For example, by utilizing such a bank, couples
could be suitably matched according to many physical characteristics and by blood type, regardless
of the time and place. Another possible use of
froien semen entails its use in insemination with
husband's semen where the husband is oligospermatic. Several split ejaculates could be pooled, and
tl:len delivered to the wife at the calculated fertile
titne. It has been proposed that men might deposit
semen in a bank for possible fvture use prior to
having a vas ·ligation. Other possible uses of semen
banks sound like science fiction stories. They include ( 1) having a supply safely stored behind
thick walls in case of nuclear attack which might
sterilize the entire male population of the country,
(2) making it possible for a man to sire offspring
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many years after he had died; and ( 3) complete
population control where all pregnancies are from
bank sperm and only those sperm known to transmit characteristics thought to be useful to the state
are dispensed, thus enabling the development of
either a "super race" or a "leader-slave culture."
In any event, various techniques have been
used to freeze sperm. Most employ glycerol as a
protecting medium. One study from the University
of Michigan used a protective medium of egg yolk,
glycerol, glucose plus sodium citrate solution, and
glycine, which was buffered at pH 7.3. The semen
sample was mixed with the protective medium, cooled
slowly to -80°C and then stored at -196.5 °C.
Thawing was performed in a 37 °C. water bath,
and inseminations were then done within 30 minutes of thawing the samples (Behrman and Sawada,
1966).
A conception rate of 40-50 % may be expected
when frozen semen is used, and this compares unfavorably with the 75% which may be achieved by
using fresh specimens for donor insemination.
This would be an indication that the fertilizing
capacity of the frozen-preserved sperm is relatively
low. In the experience which was reported from
the University of Michigan in 1968, conception had
never been achieved when a frozen-preserved specimen had been administered more than 24 hours
prior to ovulation as determined by basal temperature records. This was thought .to indicate a relatively short term of viability. Human sperm have
an apparently good motility after thawing, but despite this, fertility potential is reduced. Ackerman
was able to demonstrate a pronounced effect upon
sperm metabolism by cold-shock and believes that
the metabolic changes occurring in frozenpreserved human sperm may account for its lowered fertility capacity (Ackerman, 1968).
Pedersen and Lebech found that most cells
showed varying and often pronounced ultrastructure
changes after a routine method of freezing for semen storage (Pedersen and Lebech, 1971). The
most conspicuous changes were found in the acrosome region, the anterior segment of the acrosome
becoming increasingly swollen, the content thinned
out, and the outer acrosome membrane becoming
tortuous and discontinuous. As a result, the anterior
end of the spermatozoa loses the cell membrane
and the anterior segment of the acrosome. Changes
in the mitochondrial matrix and in the endpiece
were also noted. As the acrosome has previously
been shown to contain enzymes which probably
play a role in lysing the zona pellucida during pene-

tration, it seems probable that morphologic chqnges
in this region result in enzyme changes. It is possible that the changes reported here were influenced
by the protective substance in which the spermatozoa were mixed rather than by the freezing
itself, nevertheless, the structural changes did follow an accepted method of sperm preservation.
Because of the lowered conception rate and
the ultrastructure changes associated with frozen
semen, we do not think that t.his technique is ready
for routine clinical use, but believe that its present
usefulness is in an investigational setting.
Artificial insemination in appropriate cases, using fresh human semen from either husband or
donor, will result in a high pregnancy rate and will
successfully treat infertility.
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Our Growing Numbers*
ALLAN C. BARNES, M.D.
Vice-President, Biomedical Sciences, Rockefeller Foundation,
New York, New York

According to Dr. Barnes: There is no one problem more immediately pressing or as crucial as the
questionable future of man's existence of terms of
our expanding population.
To stress the immediacy of the problem, Dr.
Barnes vividly illustrated by statistics the magnitude
of the world's population growth. The exponential
curve yielded by calculations of this rate of growth
leads Dr. Barnes to state, unequivocably, that " ...
we have about six hundred years at the present rate
of growth before every man, woman, and child on
this globe has one square foot in which to stand.
This calculation includes the polar caps, northern
Siberia, and southern Siberia."
Because we live in a finite world, Dr. Barnes
points out that infinite population expansion is impossible. Analogous to the life-support system for
the astronauts, "We are locked in a little capsule
that has been thrown up into the air and we are orbiting the sun. Nothing that is not already here is going
to be delivered to our door." Presently, elements
critical for man's existence, such as calcium and
nitrogen, cannot be replaced once depleted. Consequently, "Zero population [growth] is going to become a necessity. And the later the year at which we
achieve it, the lower will be our standard of living."
Recent observations made by Dr. Barnes during
travels to several underdeveloped nations reveal that
the problem there is not so much a problem of living
space, as " . .. that they cannot maintain the supporting structures for what we call society." That is, the
existing facilities to cope with their present population are so inadequate as to be nearly nonexistent.
When this predicted population over-growth occurs,
it will be impossible for a self-sustaining nation to
retain its socio-economic equilibrium.
Statistics quoted by Dr. Barnes indicate that the
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United States now faces a precarious situation. Presently, our population doubling time is approximately
75 years, but worse, our pollution factor is even
greater. In addition, America is the consumer of
55% of everything that is produced on the globe.
One obvious solution, states Dr. Barnes, is that "We
must start immediately to lower our standard of living so that we will have more to send out to those
around us." At the moment, however, even if we
agreed on family replacement (two children per set
of parents) , statistically, " ... we would still almost
double our numbers before we brought a halt to our
continuing burgeoning growth."
Fervently, Dr. Barnes supports the belief that the
medical profession should exert leadership in the field
of population control. His reasoning is threefold:
First, physicians should be advocates of preventive
medicine. "America doesn't practice preventive
sociology, it practices crisis sociology .. . the physician who is delivering groups of illegitimate children, who is watching unwanted pregnancies continue, has not fulfilled his obligation when he
sews up the last episiotomy. He has not fulfilled it
until he advocates a national policy toward [abolishing] unwanted pregnancies and national enforcement
that will assist those individuals who choose not to
be so afflicted." Second, " .. . it is our responsibility
because it is caused by us." As Dr. Barnes illustrates,
medical advances in the areas of vaccination, antibiotics, and nutritional changes each have had traceable affects upon our population growth. And last,
" . .. it is our problem, at least for the moment, because the weapons that will cure it are in our possession."
The weapons Dr. Barnes refers to are: contraception, sterilization, and abortion. It is important to
note that he is primarily concerned with their use on
a global basis. "Of contraception," he feels, "the
ideal method is not at the present time at hand. With
the introduction of the ovulatory suppressant steroids
and with the reintroduction of the intrauterine device, there is a tendency to relax that has proven
19
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unwarranted in its optimism." Doctor Barnes supports the continuing need for research in this field;
for example, "We need an oral abortifacient ... a
simple medication that rules out the need for the
operating room, abortions, sterile instruments, and
so forth ... and I would hope that we're within five
to eight years of that." Above all, however, " .. . in
the research field we need dignity given to this topic
. . . particularly in the face of the size of the problem."
It is Dr. Barnes's view that "Progress in research ... is progress in reaching the ignorant, the
uneducated, and the lowly motivated." That is, if we
can provide the underdeveloped nations with a simple,
inexpensive, readily available procedure, we can
hope to lower the percentage of conceptions. A sizable failure rate in preventing conception, whether it
be 8 % or 1 % , should be considered a positive indication. "On a global basis," continued Dr. Barnes,
"you have to look at the risk-benefit ratio . . .
America has fallen into the trap of not [establishing]
a balance between risk and benefit, and only looking
at the risk as far as its medical program." In other
words, " . . . you can use a considerably less safe
method and still be well ahead of the death rate
when no method at all is used. In the United States,
no form of contraception is as dangerous as pregnancy."
Doctor Barnes points out that at the present time
we have the pill, the intrauterine device, and the
condom for global use. The comparative complexity
of the pill limits its usefulness to a minority of the
people on a global basis. The intrauterine device, on
the other hand, has the advantage that people will
have to be motivated only once a year. When insertion of this device is possible by paramedical personnel, as Dr. Barnes expects it will be, reaching the
lowly motivated will not be such an arduous task.
As for male methods of contraception (i.e. with-
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draw al and the condom), statistics reveal that they
have been more effective than female methods of
contraception.
The use of surgical sterilization and abortion on
a global basis, Dr. Barnes adds, requires too many
sterile instruments, trained personnel, and scrubbed
rooms. In a modern society such as ours, Dr. Barnes
advocates sterilization and abortion on demand .
Globally, however, his advice is " .. . do all you can
as fast as you can, but I'm afraid it isn't going to
have a statistical recognizable effect."
The contributions obtainable from prostaglandins, according to Dr. Barnes, are still uncertain. Presently, their cost is too high to enable consideration
on a global basis. "It takes about forty dollars' worth
of prostaglandins to serve as an interrupter of early
pregnancy or as a [luteolytic] agent, and that multiplies out to too much when you're beginning to talk
about the percentage of people we need to reach."
Because of the mounting statistical evidence, Dr.
Barnes cannot understand why concern for population expansion does not overshadow every other
problem facing today's world. It is his contention
that in our crisis society, people tend to ignore that
which either does not touch them personally, or is
not immediately grave or perilous. In order to bring
proper attention to the problem, people must be
reached on a personal basis. As a means of demonstrating the seriousness of the problem, Dr. Barnes
suggests giving the public something to focus on;
possibly a poster campaign with a "population
baby" as the central theme, somewhat similar to the
campaign mounted by the March of Dimes or
Cerebral Palsy.
Even in the event of immediate public response
and worldwide mobilization to counter the problem,
Dr. Barnes is skeptical. "What is the solution? I'm
not sure I know," said Dr. Barnes, " . .. it is entirely
possible that anything we do may be too little and
too late."
MCV / Q STAFF

Fetal Abnormalities of Metabolic Origin*
PETER MAMUNES, M.D.
Associate Professor of Pediatrics,
Medical College of Virginia, Richmond, Virginia

The subject of my discussion is prenatal diagnosis of genetic disorders of a metabolic rather
than a chromosomal nature. Whereas the chromosomal defects are the result of either the transmission of a translocated chromosome from a single
parent to its offspring or an error in meiosis or
mitosis, almost all metabolic disorders are inherited
in an autosomal recessive fashion. Therefore, except in rare instances, the only clue to the possible
presence of an inborn error of metabolism (IEM)
in the fetus is that a previous child of the parents
has had the disorder. This history identifies both
mother and father as heterozygotes for the deleterious gene and thus forewarns that each subsequent
pregnancy is at a 1 : 4 risk of yielding the disorder
again. By studying the amniotic fluid of the at-risk
fetus, it is now possible to determine if the disorder
is present, and if so, to prevent its occurrence by
therapeutic abortion. My main purpose is first to
review the status of the art of amniocentesis and
biochemical analysis of the material thus obtained,
and then to examine the impact this procedure will
have on the incidence and management of the
IEM.
Amniocentesis in the second half of pregnancy
for the diagnosis and treatment of erythroblastosis
has been widely used for almost two decades with a
minimum of morbidity or mortality to the mother
or fetus . Theoretical risks of the procedure (fetal
abortion, puncture, or induced malformation, and
maternal bleeding, infection, or sensitization) had
not been reported when the accumulated experience
of 500 amniocenteses during the first half of pregnancy were reviewed one year ago (Nadler: BD,
1971). Prior to the 10th week of gestation there are
less than 30 cc. of amniotic fluid present, and the
uterus has not yet risen outside of the pelvis. Because of these facts, a transabdominal approach at
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this time is usually unsuccessful and the transvaginal
route is attendant with a high risk of complications
(especially abortion) (Fuchs, 1971). For these reasons the procedure is usually withheld until the
13th to 14th week, at which time approximately
100-120 cc. of amniotic fluid are present, and the
uterus can easily be positioned to the anterior midline by bimanual examinations. Most investigators
do not use placental localization, and they accomplish the procedure on an out-patient basis. In the
combined experience of four investigators only
11 % of 353 taps had to be repeated in order to get
adequate material; initial failure in the majority of
cases was due to contamination by gross blood
(Nadler: BD, 1971).
Almost all of the cells present in the amniotic
fluid are of fetal origin (either from amnion or
skin), and some are viable. If the removed fluid is
placed in a siliconized container, the cells will not
adhere to the walls, and they can be shipped by
mail over a 48-hour period or stored overnight in a
refrigerator. When these cells are isolated from the
amniotic fluid by centrifugation and placed in
appropriate tissue culture media, their growth and
multiplication rapidly ensues. After. two subcultures
and a total of four weeks of growth, hopefully a
sufficient number of cells is present for analysis.
Depending upon the disorder, the biochemical test
performed is the measurement of either specific
enzyme activity or of possible accumulation of a
substance (such as mucopolysaccharides). Unfortunately, tissue sufficient in quantity to perform the
desired test can be obtained only 75-90% of the
time (Nadler: SM!, 1971); with chromosomal
studies, success rates of 95-99% have been
achieved (Nadler: BD, 1971; SM!, 1971).
The major premise utilized with this procedure
is that these cultured amniotic cells accurately reflect the specific characteristics of the disorder in
question. Previous studies of skin fibroblast cultures
have proven that these cells do reflect the deficient
state of the whole organism in most disorders.
21
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When the amniotic fluid cells are first removed
they have the morphological appearance of epithelial cells, but in culture they take on the biochemical and morphological characteristics of fibroblasts. However, many factors affecting the enzyme
activity of these cells must be considered before
proper interpretation of results is possible (for
example, stage of gestation, stage of growth of cells,
degree of cell confluency). If one also remembers
that these techniques must be refined to the point
where the investigator can accurately differentiate
the heterozygote from the homozygote, then hopefully he is left with the highest regard for the
complexities of this diagnostic procedure.
In addition to the use of cultured amniotic
fluid cells, biochemical analysis of uncultured amniotic fluid cells or of the amniotic fluid itself may
provide sufficient information to make an accurate
prenatal diagnosis. Although presently less than a
half-dozen disorders can be detected by these
methods (Nadler: BD, 1971), we hope further refinements will serve to increase this number, because such progress would obviate the minimum
4-week delay required to culture. Using cultured
cells to establish the diagnosis leaves only a precious week or two to effect any needed abortion,
as there are substantial medical, if not legal, restrictions to performing a therapeutic abortion
much after the 20th gestational week.
Now that we have briefly described the capabilities and limitations of the procedure itself, let
us examine how its usage can affect our present
management of the IEM. The various modalites
of treatment presently utilized (for example, limiting
substrate, providing deficient end product), for the
most part, do not attack the basic problem-that
of decreased enzyme activity. Recently, there has
been much discussion regarding the feasibility of
gene therapy, that is, the isolation of some of the
patient's somatic cells, the alteration of their genetic
endowment in vitro, and their replacement in the
individual. Other possible methods of providing the
deficient enzyme include organ transplantation or
specific enzyme replacement, but none of these approaches (particularly gene therapy) appears feasible in the next few years.
The only preventive measures available in the
past were genetic counseling and abortion of male
fetuses of mothers carrying a serious sex-linked
disease such as muscular dystrophy (the sex of the
fetus can be fairly accurately established by a study
of the sex chromatin status of uncultured or cultured amniotic fluid cells). Genetic counseling is a

good preventive measure because the majority of
parents given a 1 : 4 recurrence risk will be deterred from future pregnancies, especially where
the disorder is lethal or uncontrollable and where
there are already one or more normal children in
the family. But what of the parents whose first
child has a serious inborn error of metabolism and
who wish a normal child but are rightfully fearful
of the 1 :4 recurrence risk? This is where the amniocentesis and subsequent determination of the
specific enzyme content of fetal cells is especially
useful. I presently have two sets of young parents,
each with an infant with Hurler's syndrome, who
wish to have their first normal child. Only 3-4
laboratories in the country have developed the necessary techniques for the in utero diagnosis of this
condition. Should one of these laboratories agree
to monitor the pregnancy, and if the parents consent to an abortion if studies show an involved
fetus, either the amniotic fluid (with the cells) or
already cultured cells would be mailed to that laboratory.
At the present time there are less than twelve
laboratories active in the prenatal diagnosis of the
IEM-most, if not all, of these operate in a research rather than service capacity. A coordination
of these various centers is needed because no one
laboratory can perform all the available tests. As
of one year ago there had been less than 25 therapeutic abortions performed in the United States
for proven fetal metabolic disorders (Nadler: BD,
1971). This number would have been much higher
had the biochemical determinations been more
readily available.
What effect will this development have in reducing the actual number of infants born with
metabolic disorders? One should remember that at
present we must have an index case before knowing that we should monitor future pregnancies.
Therefore, the birth of a majority of patients with
IEM will not be prevented. Making the assumption that the goal of a family is to have two normal
children, Motulsky has calculated that performing
therapeutic abortions on all fetuses found to have a
metabolic disorder (after one sibling involvement)
will only reduce the incidence of that disorder by
12.5-34% (Motulsky, 1971).
In order to substantially reduce the incidence
of these disorders we would need to identify which
parent pairs are heterozygotic for the same deleterious gene before the delivery of their first affected
child. It would be impractical to screen all prospective parents for heterozygosity for most of the
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over 150 autosomal recessive IEM, because either
the disease is so rare, or the test is too difficult to
perform on a mass basis. However, it is presently
feasible to screen certain high-risk groups for certain disorders-for instance, sickle trait testing for
Blacks and the measurement of serum hexosaminidase A (for Gaucher's disease) in Ashkenazi Jews.
Also, because of its prevalence in Caucasians, mass
screening for the gene for cystic fibrosis should be
performed once a simple reliable test is developed.
Many ethical, moral, legal, and theological
issues are raised with our ability to define the
metabolic status of the fetus. Time does not permit
any in-depth discussion of these matters, but Jet me
pose two questions as examples:
1. Should one abort a fetus who has galacto-

semia, pyridoxine-responsive homocystinuria, or phenylketonuria? These disorders
are severe if untreated but the prognosis is
good with dietary restriction or vitamin
supplementation.
2. Should one induce an abortion where only
one of nonidentical twins has an untreatable metabolic disorder?
At present it is felt that the final decision must be
left to the parents, with the obstetrician and geneticist providing informed but impartial counsel. Per-
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haps shortly, each center involved in prenatal diagnosis will establish a board of physicians ,and lay
people to reach a consensus i11 each given case.
In summary; it is now theoretically possible to
diagnose approximately 40 different inbor,n errors
of inetabolism in a fetus early enough in gestation
to perform a therapeutic abortion. However, most
of these disorders are extremely rare, the techniques laboriOus, and diagnosis possible ~nly . after
one sibling is already involved. For now, higher
priority should be given to the development of
procedures for massive heterozygote screening and
iptrauterine diagnosis .of more common recessive
diseases such as cystic fibrosis and sickle cell anemia.
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Fetal Abnormalities of Viral Origin*
PAUL D. PARKMAN, M.D. AND HARRY M. MEYER, JR., M.D.
Laboratory of Viral Immunology, Division of Biologics Standards,
National Institutes of Health, Bethesda, Maryland

The high incidence of acute infections known
to occur in pregnant women contrasts with the
relative rarity of fetal damage and attests to
the efficiency of the mechanisms by which the
fetus is protected in utero.
The events shown in Fig. 1 summarize some
of the obstacles which a virus must overcome in
order to reach the fetus and produce defects. An
effective exposure is required to allow the virus
to multiply locally in the maternal tissues at the
portal of entry. If a viremic phase results the ,.Virus
becomes disseminated and the placent~ riia:Y' be
infected; depending on the type of infottion,
placental damage may or may not result. If the virus
successfully crosses the placental barrier, the fetus
may become infected either by way of fetal viremia
or by contiguous spread through the membranes.
Since maternal viremia is necessary to initiate this
chain of events, the fetus is naturally protected
against vin1ses which seldom invade the blood
stream. Most of the viruses causing respiratory
diseases fall into this category. The maternal immunologic system provides significant protection
by circulating antibodies stimulated by earlier natural or vaccine induced infection. Even if the mother
is susceptible and the infection is associated with
viremia, the virus may still be effectively stopped
by the placental barrier; this has been shown to
occur commonly in both rubella and cytomegalovirus (CMV) infection. If, on the other hand, the
virus reaches the fetus, to produce a teratogenic
effect the virus must have a delicately controlled
pathogenicity allowing a chronic infection to be
established compatible with a period of continued
growth and development. Only two or perhaps
three human viruses have been documented to
have the ability to produce such infections. These
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Fig. I-Events leading to fetal infection and disease.

include rubella virus, human cytomegalovirus, and,
possibly, herpesvirus hominis (herpes simplex virus).
Of these three hutrian viruses, the teratogenic
effeCts of herpes simplex virus are the least
documented. There are 5 reports in the literature
suggesting that genital herpes infections acquired
early in pregnancy may be associated with congenital malformations. Defects seen in these .5 infants
included microcephaly, microphthalmus, and char~
ioretinitis. Skin lesions were present either at
birth or soon thereafter in 3 cases arid encephalitis was present in 1 instance. Investigation of the
infants with microcephaly for other possible infectious etiologies includirig cytomegalovirus and
toxoplasmosis infection gave negative results. The
association of herpes simplex virus with eye and
central nervous system (CNS) defects in these cases
is highly suggestive that this virus may on occasion
be teratogenic; the role of herpes simplex virus in
this regard deserves further investigation (Nahmias,
et al, 1970).
As the result of a decade of intensive interest,
rubella represents the most adequately studied
MCV QUARTERLY 8(1): 24-28, 1972
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congenital infection producing fetal defects (Krugman, 1969). It also represents the only teratogenic
virus infection currently controllable through the
use of vaccine.
Rubella is recognized to occur every year in
sporadic outbreaks covering restricted areas. Since
1928 major epidemics of the di~ease involving the
entire country or large sections of the country have
occurred at 6- to 9-year intervals. Rubella shows
the same prominent seasonal pattern of other diseases transmitted by the · respiratory route. The
maximum incidence of the disease occurs during the
winter and spring months, with very low rates in
summer and fall. In a nonepidemic year, it has
been estimated that the occurrence of rubella in
pregnant women is in excess of 8/10,000 pregnancies. In an epidemic year, this rate may increase
30 to 40 times.
·
The clinical features of natural rubella virus
infection vary from the clinically inapparent to
an illness of sufficient severity to be confused
with measles. Children before the age of puberty
tend to have a mild illness consisting typically
of 3 days of low-grade fever, seldom exceeding
101 °F, rash, and generalized lymphadenopathy.
Nodes are especially prominent in the posterior
cervical region. In adults, particularly women,
the illness is often more severe. The earliest evidence of infection is lymphadenopathy. The nodes
may be tender and the enlargement often persists
for several weeks after the onset of symptoms.
The rash is variable in appearance. Ordinarily,
it first becomes apparent on the face and spreads
rapidly to the trunk and upper extremities. It may
have begun to fade on the face by the time it becomes fully developed on the lower extremities.
Prominent respiratory tract symptoms do not occur.
Women with . rubella sometimes also complain
of headache, malaise, myalgia, painful gums, and
paresthesias, particularly of the hands.
Rubella is the only viral infection in this
country which is frequently associated with arthralgia and arthritis. Age and sex have a marked effect
on the frequency and severity of these symptoms.
In a recent retrospective survey following an
epidemic, 25 % of prepubertal children ~xperienced
joint-related symptoms. After puberty there was a
sharp increase in the . incidence of arthralgia and
arthritis, and with increasing age between menarche
and menopause the frequency and severity of involvement increased progressively. Commonly the
joint symptoms followed the rash by several days,
although in some instances arthritis preceded the
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rash . or was delayed until several weeks after the
onset "'of 'infection. The joints involved, in order of
frequency, were the proximal interphalangeal
joints, the knees, wrists, ankles, and the metatarsophalangeal joints. Symptoms ordinarily subsided in 1 to 14 days but some patients, notably
older women, experienced recurring symptoms
lasting for a year or more. Even in such instances
symptoms have cleared and there has been no
residual deformity. There is no evidence that these
reactions predispose to the development of chronic
arthritis.
· ·In the typical case, virus may be recovered
from blood and respiratory secretions one to one
and a half weeks prior to the onset of rash.
Viremia disappears shortly after the onset of rash
in association with the appearance of circulating
antibodies. Presence of virus in the respiratory
tract diminishes more slowly; virus may continue to
be recoverable for several weeks. Neutralizing
and hemagglutination-inhibiting (HAI) antibodies
develop promptly after the exanthem appears and
persist for years, probably for life. The CF
antibody response is slightly delayed and may
decline over · a period of years. The widespread
availability of the HAI test has made the rubella
serodiagnosis of critical cases available to everyone. Establishing an accurate diagnosis is nowhere
more important than in the instance when a pregnant woman is exposed to rubella. Under such
circumstances, an initial serum specimen should
be obtained as soon as possible after exposure and
tested for antibodies to determine the immune
status of the patient. Subsequent sa.mples should
be collected in early convalescence · if disease
develops and in asymptomatic patients at 4 and
6 weeks after exposure. These later samples tested
in parallel with the earlier ·specimen will document
if infection has occurred.
In 1940, a communication appeared in a prominent medical journal protesting interest in rubella
as inappropriate since it was "an entirely inconsequential disea.se." This misconception was laid to
rest within the next year by the astute observations
of an Australian ophthalmologist. This was the contribution of the late Sir Norman Gregg, who opened
the field of viral teratogenesis as a result of his
discovery of the association between maternal
rubella, congenital cataract, and heart defects.
Over the years since Gregg's original observations,
it has become apparent that virtually any organ
system of the developing fetus may be damaged.
The fetal infection may be severe enough to

26

PARKMAN AND MEYER: FETAL ABNORMALITIES OF VIRAL ORIGIN

cause spontaneous abortion or stillbirth. Congenital
involvement often present in the newborn period
included deafness, heart disease, retardation, meningoencephalitis, microcephaly, eye defects, including congenital cataract, retinopathy and glaucoma, purpura, anemia, hepatosplenomegaly with
hepatitis an~ jaundice, pneumonitis, · and bone
lesions.
The earlier in pregnancy maternal rubella
occurred, the more likely jt was that the defects
would be multiple and severe. Follow-up data
indicated that infectjon. during the nrst 2 months of
gestation was associated wjth the highest incidence
of heart, eye, and CNS defects; fetuses infected in
the 3rd month had significantly fewer heart and eye
defects. All types of malformations declined in
those babies who had been infected during the
4th month (Cooper, et al, 1969). It ha~ been estimated that the chances of anomalies when maternal infection occurs during the first month is in
excess of 50%, in the second month about 22%,
and in the 3rd through 5th months, 6% to 10%.
In the pathogenesis of congenital rubella,
viral invasion of the placenta occurs during the
peri9d of materna·l viremia. Replication of virus
in the placenta produces focal areas of mild inflammatory response and scattered damage of the
endothelium of the chorionic blood vessels. Extension of the infection to the fetal circulation permits the virus to reach the developing organs
where a persistent infection ensues. This infection
may be localized or widely disseminated throughout
the fetal tissues. Virus shedding in pharyngeal secretions and urine and the presence of virus in the
tissues can be demonstrated throughout the neonatal period; in those infants with severe rubella
defects, particularly, virus shedding may continue
sporadically int~ the second year. The presistence
of virus is of epidemiological importance since
rubella infected infants can transmit their infectiOn
to nursery personnel and other contacts; thus · it
is important to limit the contact of such infants
with pregnant women in the hospital and after
discharge;
·
Antibody responses in maternal rubella, as
with most infectious diseases, consist of the early
appearance of transient IgM antibody, promptly
followed and eventually replaced by the IgG class
of antibodies. It is the latter which are responsible
for the long-term persisting rubella antibodies.
The situation in the infected fetus is more complex.
Maternal IgG is transplacentally transferred. The
infected fetus begins to produce his own immune

substances, in the form of IgM antibodies, at some
period during the second trimester. At birth the
titer of antibodies in maternal and infant sera is
very nearly the same. The infant's antibodies are
made up of both transplacental IgG and endogeneous IgM. As many as 80% of rubella infants will
have an ·elevated IgM serum protein fraction during the neonatal period. During the first year of
life, passively acquired IgG declines. The production of infant IgG appears during the early
months of life, and late in the first year replaces
IgM as the predominant rubella antibody.
· At · the present time, short of therapeutic
abortion, there are two methods for averting
congenital rubella : ( 1) passive immunization of
exposed pregnant women using commercially
available immune serum globulin (gamma globulin); and (2) the use of live attenuated rubella
vifus vaccine for active immunization of nonpregnant subjects.
Gamma globulin has been commonly used
for many years for the prevention of rubella infection in exposed pregnant women. The efficacy
ofthis procedure has been a matter of controversy.
There is no question that large doses of globulin
given prior to exposure are effective in decreasing
the incidence of infection and the clinical manifestations among those who acquire infection. In
tfle ordinary circumstance in which globulin is
used, however, exposure has already occurred
several days earlier. In such cases the beneficial
effect of globulin · is less well documented. In fact,
~hildren with rubella syndrome defects have been
born to mothers given appropriately timed adequate doses of gamma globulin. Carefully performed
virologic studies, designed to mimic the usual postexposure situation encountered clinically, failed to
show protection against experimental infections,
although there was some effect in diminishing the
duration of viremia. From these data, it is obvious
that globulin is unreliable as a measure for the
prevention of congenital defects. On the other hand,
it is impossible to be certain that globulin, through
reducing the duration or level of viremia, might
not have some effect in reducing the risk of fetal
infection. On this basis, and because it represents
the only currently available measure which might be
of help in this situation, our feeling is that the
continued use of large doses (20 ml of gamma
globulin) is justifiable in circumstances where interruption of pregnancy is not desired.
Live rubella vaccines are prepared in cell cultures and induce immunity by producing a modi-
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fied rubella infection in susceptible persons (Meyer
and Parkman, 1971). The 3 vaccines currently
available are produced in duck embryo cells by
Merck, Sharp, and Dohme (Meruvax®), in canine
renal cells by Philips Roxane, Inc. (marketed by
them as rubella virus vaccine, live) and by Parke
Davis and Co. as Rubelogen®, and in rabbit renal
cells by Smith Kline and French, Inc. (Cendevax®).
In children, vaccine induced infections are usually
asymptomatic, while adults may develop rubella
like symptoms. Such symptoms may consist of
an evanescent rash, lymphadenopathy, and transient peripheral nerve and joint involvement. The
most troublesome complaints have been related
to occurrence of arthralgias, arthritis, and paresthesias; these symptoms follow a pattern of distribution similar to that seen in the natural
disease. They appear within 3 to 5 weeks after
immunization, but on occasion may be delayed until
8 weeks postvaccination. Reaction rates in women
of childbearing age range from 10% to 60% and
as in the natural disease are in part related to the
age of the woman; reaction rates have been highest
in the older age groups. The immunogenicity of the
vaccine used also affects the likelihood of reactions. The canine renal cell prepared vaccine which
produces higher antibody levels was also responsible
for higher reaction rates than vaccines prepared in
duck or rabbit cells. The joint manifestations are
usually mild; however, occasionally a patient may
continue to have residual subjective complaints lasting for weeks or months. Persons with arthritic
manifestations have not shown the development
of later chronic joint disease.
Rubella vaccines stimulate antibodies in 95 %
to 100% of recipients between the 2nd and 4th
weeks postvaccination. Thus far, these antibodies
have been shown to persist without significant
decline throughout the 5-year period of observation since the earliest vaccinations were performed.
In the United States, efforts of mass vaccination programs have been directed toward the immunization of children. This approach is designed
to reduce the opportunities for spread of virus
by decreasing the susceptible childhood population most responsible for initiating and maintaining
epidemic rubella. At the same time, the desirability
of providing protection for the susceptible adult
women is also recognized. Immunization of this
group presents special problems. Arthritic reactions are more common in this age range; most important, however, is the risk of immunizing women
in unrecognized early pregnancy or women who may
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become pregnant immediately after vaccination. In
such situations, it has been shown that in susceptible
women the attenuated virus can produce chronic
placental infection which may be transmitted to
the fetus. Generally, when vaccinations have been
performed early in gestation, therapeutic abortion
has been performed. Too few pregnancies have
proceeded to term to determine the possible consequences of fetal infection with vaccine virus. Thus
it is highly important when vaccinating adult women, to insure that the patient is not pregnant
and will not become pregnant for at least two
months after immunization. Pretesting of women
for HAI antibodies is recommended and will exclude the necessity for using vaccine in immune
women.
If vaccines are used extensively and if the
immune status of the population can be maintained at a high level, it seems possible that rubella
control can be achieved.
In comparison with the abundance of information available about rubella, knowledge of the
epidemiology and pathogenesis of congenital CMV
infections is limited. Thirty to sixty percent of
childbearing age women have detectable antibodies. Infection during the reproductive years
may be quite common. Serologic responses occurred
in 3 % to 5 % of pregnant women in two urban
centers studied. Information is not currently available concerning the frequency with which maternal
infection is transmitted to the fetus. It is also
unclear what proportion of fetal infections are
( 1) inapparent, (2) silent at birth but produce
clinical manifestations later, or (3) result in classical
cytomegalic inclusion disease. The reason for this
poor documentation is in part attributable to the
fact that maternal infections are subclinical. Rarely
acute CMV infection in the adult may mimiC infectious mononucleosis. Diagnosis of maternal CMV
infection by virus recovery is hampered by the
observation that virus may be shed in the urine
for periods up to 2 years following initial infection;
thus recovery of virus from a pregnant woman does
not necessarily indicate acute disease.
The occurrence of the majority of congenital
CMV infection in babies born to young primiparous
mothers, suggests that intrauterine infection is most
commonly acquired by the fetus during the viremic
phase of primary maternal CMV infection. Fetal
infection may occur in the first trimester (Davis,
et al, 1971) and perhaps later in pregnancy as well.
As in rubella, it has been shown that placental infection may occur without infection of the fetus .
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Congenital CMV infection in 2 siblings born
within 8 months of one another has been recently
reported (Emil, et al, 1970). The possibility of
such an occurrence should not be overlooked in
the follow-up of women who have borne a CMV
affected child.
Adding to the complexity of the CMV problem is the observation that multiple antigenic variants of the virus exist; the significance of this variation in the virus for immunity and the possibility of
reinfection is unknown.
The features of classical congenital cytomegalic
inclusion disease include, like rubella, defects in
CNS, eye, and hepatic and bone marrow function. Microcephaly and hydrocephaly, encephalitis,
cerebral calcifications, convulsive disorders, chorioretinitis, blindness, hepatosplenomegaly with jaundice, thrombocytopenia with petechiae, anemia,
and interstitial pneumonia all can occur. Unlike
the rubella syndrome, cataracts and heart defects
are not seen.
As in congenital rubella, virus can be recovered from throat, urine, and blood of affected
live born children and from multiple tissues of
aborted or stillborn fetuses. Virus recovery from
clinical specimens, unless accomplished in the immediate newborn period, cannot be taken as certain
indication of an etiologic relationship between
defects and CMV infection since these viruses can
be recovered with some frequency from urine of
asymptomatic children. The demonstration of elevated serum IgM and the persistent occurrence
of specific CMV IgM antibodies in the serum of
newborn infants provides convincing evidence of
intrauterine infection (Sever and White, 1968;
Alford, et al, 1967).
Aside from the experimental use of chemotherapeutic agents which inhibit replication of DNA
viruses in children with the congenital disease, no
methods of prevention or treatment are currently
available.
What new developments are likely to occur
which might be important from the standpoint
of congenital infections? Several recent reviews
have explored the status of other viral agents in
producing abortions, stillbirths, and neonatal disease. It has been speculated on the basis of
epidemiologic studies that other agents including
varicella, vaccinia, mumps, influenza, and measles
viruses may possibly induce fetal defects (Sever
and White, 1968; Hardy, 1965). The etiologic relationship of these viruses with congenital defects
are not in hand, but with additional study might

yet be proven. Perhaps other mechanisms than
those active in rubella and CMV infections will
be shown important. An even more interesting
possibility relates to the cancer virus field. Impressive evidence is available indicating that many
tumors of amphibians, birds, rodents, and cats are
caused by viruses. The study of animal model sys··
terns in chickens and mice indicates that RNA
leukemia viruses may be transmitted "vertically,"
that is, directly from mother to embryo. The incidence of malignant disease in the congenitally infected animal is higher than that seen in the adult
host infected by contact. Could such situations
exist in man? Enough parallels exist between the
human and animal diseases to make this a tantalizing possibility. Perhaps as techniques for searching out human oncogenic viruses become more
sophisticated, similar agents may one day be recognized as causing highly important congenitally
acquired infections.
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Psychological Abnormalities of Sexual Identification*
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The normal process of development of sexual
identification slides almost unnoticed through welldefined, but overlapping stages to a definite end
point. That end point is an individual who senses
that his core gender, male or female, is consistent
with the body morphology, the external genitalia,
the chromosomal configuration, and the hormonal
balance. Also, there must be the development of
personality traits, masculine or feminine, consistent
with the sense of core gender. Finally, although
somewhat outside the scope of our present discussion, there must be the establishment of a role
or life style in adulthood in accordance with the
first two steps. The end point normally is sexual
behavior acceptable to both the individual and to
society, that is, heterosexual behavior in an individual who is comfortable with himself.
There are, then, three steps to mature sexual
identification. The first and the most basic is the
establishment of core gender, a sense of maleness
or femaleness. The second is the establishment of
personality traits, masculinity or femininity, which
are layered upon the core gender but, as we shall
see, are not necessarily consistent with it. The final
step is the establishment of a life style or role
which produces that obscure thing we call adult
maturity. Let us take a closer look at the steps
with emphasis upon the female.
The Core Gender. Core gender is the inner
sense of being male or female and is not synonymous
with masculinity or femininity (Stoller, 1965). Maleness /femaleness and masculinity/femininity are entirely different concepts, and in abnormal situations
they may be in conflict with each other. Core
gender is a basic concept universally recognized
in all cultures. The sense of masculinity and femininity largely determines the use the individual makes
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of the core gender and is far from being universal
(Mead, 1955). It varies markedly from culture
to culture and may even determine specific subcultures in a given segment of society. This is not
true of core gender wherein the sense of maleness
or femaleness does not change.
The most important and the most accurate
somatic sign of core gender to an , individual and
to his social milieu is the configuration of the
external genitalia. One of the first things noted about
the newly delivered baby is its genitalia. This quick
and automatic examination is the first step, and in
the vast majority of cases the only necessary step,
toward determining the direction of that infant's
development of a sense of core gender. When the
parents are told the sex of a newborn infant, a
complicated series of attitudes, feelings, and activities are set in motion in the parents, and later in
the total social group. These factors are of primary importance in deciding whether or not that
given individual will sense itself as male or female
in adulthood.
Somatic gender and psychological gender do
not always coincide in a small percentage of cases.
Nature's errors have shown us that there are
several variables which may enter the picture.
These errors which produce congenital abnormalities have furnished us a natural laboratory in which
to study the process of sexual identification (Money,
Hampson, and Hampson, 1955). The variables
which go into the picture are: chromosomal sex,
gonadal sex, hormonal sex, internal reproductive organs, external genitalia, and finally, the
emotional set of the parents.
The identity of core gender for practical purposes appears derived from three major sources:
( 1 ) the anatomy and physiology of the external
genitalia; (2) the attitudes of parents, siblings, and
peers toward the child's gender role; (3) a biological force that may modify or counter the effects
of the first two in rare cases. These factors cannot
29
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be totally dissected from each other. The third
factor, the biological force, is theorized by Robert
Stoller from those rare cases which develop a core
gender identity at variance with both the anatomy
of the genitalia and the apparent attitudes of the
parents toward the child (Stoller, 1964) .
By far the most significant factor in the development of gender identity is the attitude which the
parents associate with the gender assigned to the
child at birth. This original assignment is made upon
the appearance of the genitalia. The complicated
maze of cues and signals which come from this
include name, personal pronouns, type of dress,
haircut, toys, amount of time the baby is handled,
and more subtle attitudes. However, there are
many cases in which a definite gender assignment
has not been made at birth, and the child has been
reared in an ambiguous situation. This allows for
three possible gender assignments at birth: male,
female, and no definite assignment. A child who
has been reared to be unequivocally male or female appears firmly fixed in this gender role by
the age of two and one-half years, but the child
reared by parents who are uncertain of its gender
role -may see itself as neither male nor female at any
year of life (Money, Hampson, and Hampson, 1957;
Money, Hampson, and Hampson, 1955). This
means that except for those rare, confused cases,
core gender identity is fully established before two
and one-half years of age, and that the sense of
maleness or femaleness then becomes increasingly
difficult if not impossible to change. Stoller has
found that almost every successful report of
changing sexual assignment after this age has involved an individual whose parents have not been
able to see it as definitely male or female (Stoller,
1964 ).
Money and his co-workers verified this in
their study of intersexed patients (Money, Hampson, and Hampson, 19 5 5) . In their first series of
76 cases raised with a gender assignment contrary
to the variables of somatic sex, only four had not
accepted the assigned sex. They found that an
intersexed individual may establish a gender role
opposite to the appearance of the external genitalia even though this is the most important sign
to the parents and to the patient in determining
gender identity.
There are many other studies which support
the conclusion that a clearcut assignment to a core
gender in early infancy leads to a psychological
gender identity which remains fixed, even when
that gender is incompatible with the somatic

measures of sex. The practical implication is that
a baby born with sexual anomalies of any sort
should be diagnosed as rapidly as possible so that
the proper sexual assignment can be made. Much
attention and importance should be placed upon
the external genitalia and upon the ease with which
the abnormalities can be surgically reconstructed
to be consistent with the diagnosed sex. Reassignments of sexual role after the third year should be
undertaken only when it can be determined that
the child has not accepted the role of either male
or female. If surgical revision is feasible, these
patients may make the switch without undue emotional turmoil. These will be the children whose
parents have raised them in no particular gender
assignment and communicated this ambiguity to the
child.
These observations of nature's errors-intersexed patients-have received support from the
imprinting studies of Konrad Lorenz and from
H. Harlow's experiences with monkeys (Lorenz,
1952; Harlow, 1962). These studies on animals
have shown that the early experiences of the animals determine how they will function sexually
when they become adults. There is no evidence
that imprinting in this manner occurs as specifically
in the human being as in its primate relatives,
but the phenomenon of this permanent identification supports the concept that certain sensory experiences may influence the development of reaction patterns in the central nervous system.
Such confused sense of core gender can occur
when there are no abnormalities of a morphological
or physiological nature, and when it does, the
condition is called transsexualism which simply
means the mind or psyche of one sex trapped in
the body of another. Christine Jorgenson made
this a respectable medical study in this country
some 20 odd years ago when she became a woman
after many years of maleness. Transsexualism
probably represents a form of imprinting in which
the individual is programmed to the core gender
opposite to the morphological and genetic sex
(Benjamin, 1966).
An example of this condition is a young lady
who a few years ago requested that she be given
a male voice and a beard. She stated that she had
difficulty holding down her job as a carpenter once
they found out she was not a man. Dressed in male
clothing and with a short haircut, she looked much
like a boy in his late teens although she was 30
years of age. Her story was as follows:
On the same day in a rural town two sisters
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delivered babies. One sister was married, and
one was single. The married sister delivered a
male child who died immediately at birth. The
unmarried sister delivered a normal girl child who
was given to the married sister to replace her dead
infant and raised as a male child. This girl baby
was named William and called Bill. As an only
child, she became Daddy's helper around the small
ranch and had her first dress on at the age of 13
when this was enforced at the high school level.
At the age of 30, Bill could describe the acute
embarrassment of being forced to wear female
clothing.
Bill sensed herself to be a male although she
had a normal menstrual cycle, and complete endocrinological and chromosomal work-ups revealed
a perfectly normal XX individual. She had even
forced herself to have sexual intercourse in her
early 20's in an attempt to become "different" but
had found it disgusting.
Bill wanted simply to function as best as possible in accordance with how she sensed herselfas a man. She was a transsexual in the fullest
sense of the word, but whereas it is possible to
replace the penis and the scrotum with a vagina,
the opposite is surgically a bit difficult.
Thus for the first phase of sexual development
(core gender), transsexualism is the psychological
abnormality sometimes seen, and it appears to be
relatively unchangeable after two and one-half
years of age.
The second aspect of sexual identification
which may go awry is the sense of masculinity or
femininity. This is layered upon but not necessarily
identical with the unalterable core gender. The
concepts of masculinity and femininity are complicated de".elopmental processes that are culturally
and socially determined and which modify and
cover over the core gender but do not change it
(Mead, 1949). Thus, a male homosexual may
have serious doubts about his masculinity, but he
does not doubt his maleness at any time. He may
not like being a male, but he definitely knows that
he is one. Similarly, the female homosexual may
abhor her core gender to the extent of removing
every external vestige of it, but this does not alter
her knowledge of her femaleness.
Masculine and feminine identities may change
throughout life, but the most significant aspects
may be well established by the age of 6 to 7.
Social, cultural, and parental factors play determining roles in differentiating and establishing the
individual's psychological concepts of sexuality.
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At about three years of age, there is the beginning
of increased attention to the genital area as a ·mark
of progressing physiological and biological maturation. The child perceives new sensations which
lead to a marked increase in curiosity about its
body and the bodies of ' others. Children are apt
to notice that there are sexual differences, that
the outline of one body is not the same as another.
This is a momentous discovery for a child and
may lead it to ruminate about these differences
and to concoct various explanations for them. The
little girl must deal with her discovery of having
no external genitalia comparable to that of the
male. Whether or not she perceives herself as
being defective will depend upon, in most cases,
how her mother views the role of female and
whether or not the mother shows a preference
for that which is masculine.
The little girl's perception of what ~t takes to
be feminine is controlled largely by ~hether or
not she senses femininity as desirable. The father
figure plays a major role here. The' little girl must
conceptualize whether or not the father figure
approves of femininity and all that it entails. If
not, she is apt to find it difficult to accept a role
which, more or less, excludes father's approval.
Normal psychological development of sexuality in
this period requires that the mother be a desirable
figure after whom to model oneself, and that
simultaneously the father figure approve of this
role.
We are talking about what Freud called the
Phallic phase and the Oedipal period. The most
important requirement of the Oedipal period is
that the child experience a sustained relationship
to a mother and a father in their sexually differentiated roles. The Jack of a parent of the same
sex or an undesirable parent of the same sex during
this phase makes it extremely difficult to establish
a proper identification compatible with the core
gender. The Jack of a parent figure of the opposite
sex, relative or otherwise, is equally discouraging
to the development of adequate heterosexual relationships in the future.
The daugh~er · of a harsh, demanding, and rejecting father or in a home situation in which masculinity reigns supreme and all things feminine
are depreciated, can hardly see herself obtaining
desired approval by developing feminine traits.
She is apt to become an adult who se~s feminine
characteristics not only as without positive value,
but also as attributes which produce discomfort
and anxiety.
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Whereas maleness and femaleness are definite all-or-none phenomena, masculinity and
femininity are not. The latter lie upon a continuum
which produces at one end a high level of homosexuality, and at the other end, a high level of
heterosexuality. Most people fall somewhere in
between. · If we confine our discussion to the female, we can avoid speaking of the many deviations
of sexuality which occur in the male. True deviations,
with the exception of homosexuality, are relatively
rare in females.
Not so rare in the female are the many aberrations of sexuality due to defective identification
as to the feminine aspect. For example, these
aberrations almost always will be manifested as
aberrations of the personality. Over-aggressivity
or over-passivity may mean the same thing. Difficulties in relating to the opposite sex may stem
largeiy froIJl deficient identification as feminine.
The 'variou~ conditions such as frigidity, dyspareunia, prqmiscuity, and even menstrual abnormalities
may be symptomatic of deficiencies in identification. The !)!ntire attitude of a woman toward being
a wife anq ~ mother depends largely on this facet
of the 'petsonality.
. PsychologiCal problems can be manifested as
physiOlogical changes. The hypothalamic areas are
in ch'arge of the pituitary, and therefore, of much
of endocrine functioning. Just as severe stress or
fear can change menstrual function, so can prolonged · identification problems produce abnormal
physical manifestations directly through the autonomic nervous system and indirectly through the
endocrines (Sturgis, 1962) .
Let us look briefly at one example of an
aberration of the development of femininity. A young
lady came for psychiatric consultation at the age of
25, two years after her marriage to a young
lawyer. Both of her parents were physicians. Her
mother was a very competent, cold, and efficient
professional, and the father was a very outgoing,
warm, and well-liked individual. Her fantasies of
her father included this statement, "I bet he 'made'
every woman he met during his younger years."
She said this with a look pf distinct pleasure and
pride.
This lady came into treatment primarily because she was being extremely promiscuous. She
enjoyed sexual intercourse with her numerous
partners, but she could barely tolerate it with her
husband. She had, upon several occasions, become
violently ill because of the necessity to have inter-

course with him. She followed this by a hot shower
to cleanse herself symbolically.
None of this occurred when she slept with
other men. She did not have orgasms, but she
enjoyed the act immensely and never had any
feeling of dirtiness or· guilt. She wanted help for
the problem, because she recognized that such a
life eventually would become greatly complicated,
and that it was foreign to how she really felt at
some level.
This girl identified strongly with the warm,
outgoing father. The cold and aloof professional
mother simply was not a model for her. Her core
gender was perfectly normal; she knew quite def~
initely that she was female. However, she was far
from being convinced of her femininity. She had
seen femininity as a little girl as something not
desirable. She had conceptualized being like her
father, the outgoing, likeable, masculine image, as
being very desirable. The promiscuity was following the example of how she thought her father
must have acted when he had been her age, but it
a1so was a way of proving to herself that she really
was desirable. She could not tolerate sexual intercourse with her husband because this represented
to her intercourse with her own father. This is a
kind of reverse of the Madonna-Prostitute Syndrome,
sometimes called the Messalina Syndrome (Mathis,
1971). It represents an abnormality of the sexual
identification at the second step.
The third and almost final step of sexual
identification occurs in the teens with the establishment of a role. Maleness and femaleness are fixed,
masculinity and femininity are fairly definite, but
justhow one is to use these aspects in living can
still vary greatly. We will not go into this, since
the cultural aberrations are many and are beyond
the scope of this talk. It is, however, in the early
teens that the psychological abnormalities of sexual
development become openly manifest. Always they
will have been obvious to the astute observer at
the earlier years, but now they are inescapable.
The onset of puberty and the blossoming of
secondary sex characteristics may come as a great
shock to a little girl who does not like to face the
fact that she is a woman. She may see menstruation
and a budding breast as vulgar signs of something
that is undesirable. Not infrequently this leads
to great anxiety which is manifested by delinquent
behavior-almost always sexual in nature. Her
anti-social sexuality may have many meanings, but
one is to misuse or to degrade that part of her
which she does not like. On the other hand, this
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behavior may be used as a constantly recurring
attempt to prove that she really is feminine, something that actually is beyond her reach at some
level.
Heterosexual maturity requires an unambiguous knowledge of core gender and a mature identification of the masculine and feminine roles in the
society in which an individual lives. The process
by which this is obtained is complex and fraught
with innumerable dangers. Fortunately, by far the
greatest majority of people make it to the desired
maturity level quite well. A large number, however,
make up the patients which you see, primarily because they have deviated at some point in this
developmental process.
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The Surgical Approach to Problems of Sexual
ldentif ication *
HOW ARD W. JONES, JR., M.D.
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University School of Medicine, Baltimore, Maryland

At the level of chromosomes recognized morphologically in every cell, two sexes are a basic
biological phenomenon. At the level of the total
organism, these sexual differences may be seen anatomically and endocrinologically and perhaps in a
less precise way psychologically, especially as measured by behavior. In the human , various errors in
the anatomical development of the sex organs due
to genetic, environmental, or unknown causes have
been recognized and described under the general
heading of intersexuality. Poorly treated victims
of these aberrations may experience confusion, or
even crises, in sexual identification. For the most
part, such psychological difficulties can be related
to the anatomical ambiguity of the genital organs.
However, there are other individuals who, by
ordinary anatomical, endocrinological , and chromosomal examination, are quite consonant with
respect to one or the other sex but who, nonetheless, consider themselves to be of the oth er sex. In
its full-blown clinical expression, such individuals
manifest with consistent and persistent conviction
the desire to live as a member of the opposite sex
and progressively take steps to do so. Furthermore,
psychological evaluation of such individuals reveals many characteristics of the sex opposite to
their anatomical sex. Such individuals may be labeled as transsexual , and it is to the therapy of
such patients that the role of surgery has been
evaluated on a small number of patients at The
Johns Hopkins Hospital over the last several years.
While transsexualism is a disorder which
seems to affect both anatomical sexes, the gynecologist plays his principal role in the therapy of the
'' Presented at the 43rd Annu al McGuire Lecture
Series, December 2, 1971 , a t the Medic al College of Virginia, Richmond .
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male transsexual, i.e. , the anatomical male who
conside rs the difficulty to be that of a fem ale
psyche trapped within a male body. It is only with
these male patients with a female gender orientation that this discussion will deal.
Unfortunately for the therapist, the diagnosis
of transsexualism is not easy and must be distinguished from other disorders which have, or
seem to have, expressions of incongruent gender
behavior. Among these are transvestism, homosexuality, psychotic individuals with confusion in
sexual identification and gender role, neurotic
sexual problems, and exhibitionism.
Th e gynecological surgeon should not, and
indeed cannot, dispense with the wholehearted help
of psychiatrists and psychologists in sorting out
these sometimes overlapping entities. As with most
behavioral disorders , there are no objective criteria,
no specific physical findings , no laboratory test, no
pathonomonic sign by which a specific diagnosis can
be made. Nonetheless, it cannot be overemphasized
that no pains must be spared to make an accurate
diagnosis . Experience to date has made it abundantly
clear that surgery is unlikely to be appropriate and
may be devastating for those disorders which might
be confused with true transsexualism but which ,
nevertheless, exhibit signs of deviant gender role.
Thus , the male transvestite is a "cross-dresser"
at intervals for the reli ef of an insistent tension that
builds up between cross-dressing. However, he is
usually heterosexual in his relation with women and,
if married , takes the position that his wife and
children understand him and are not devastated
by his actions and cross-dressing. It would obviously
be an error to think of reconstructive surgery of
the genitalia for the transvestite.
The effeminate male homosexual is erotically
attracted exclusively to men. He may wear woMCV QUARTERLY 8(1): 34-36, 1972

JONES: PROBLEMS OF SEXUAL IDENTIFICATION

men's clothes, but apparently the compulsion to do
so is less than that of the male transvestite. He is
not heterosexual, as is the transvestite. However,
and most important, he seems to have no problem
with his own sexual identification and has no desire for transsexual surgery, except in temporary
situations such as the break up of homosexual
partners.
The true male transsexual exhibits many
phases of a female personality. This includes not
only the desire to repudiate men's clothing and
strictly male activities, but expresses itself to the
surgeon as a desire to be rid of the male genitalia
which serve as a constant reminder of a sexual
symbol and status which are regarded with repulsion as inaccurate. Also, it is generally true that
when a male transsexual is offered the option of
having a vagina constructed, which is the only
female organ which can be surgically offered, she
will invariably elect to have that procedure carried
out.
The undesirability of offering operations to
psychotic individuals with confusion in sexual
identification and gender role should be obvious.
The other disorders which might be of some confusion, such as neurotic sexual problems and the
like, are not only too trivial for surgical reconstruction but are amenable to psychiatric therapy.
One of the main reasons for evaluating surgery in the treatment of this disorder is the fact
that transsexual individuals are very resistant to
psychiatric help for their disturbance. While the
gynecologist obviously cannot speak with great
understanding and experience on the psychiatric
approach to disease, it is perhaps not inaccurate
to observe that psychiatric failure to offer help to
the transsexual stems from the fact that the psychiatrist necessarily wishes to aid the transsexual by
reorganizing the psyche to conform to the anatomical sex. This the transsexual resists and does not
want. The psychiatrist, therefore, has no handle
on the transsexual and does not have a sympathetic
patient, for the patient regards with suspicion anyone who denies what the male transsexual believes
to be the basic problem, that is, a female psyche
trapped within a male body. It is because of this
basic impasse in psychiatric therapy that endocrine
and surgical manipulation might have a role in
bringing the patient to terms with her basic conflict.
The Selection of Patients for Surgery. About
five years ago at The Johns Hopkins Hospital, a
gender identity clinic was established for the pur-
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pose of studying the problem of transsexuality
and the role of surgery in the therapy of patients
with transsexualism. This clinic consists of several
individuals from various disciplines. Psychiatry is
very heavily represented, and a psychiatrist is chairman of the committee. Representatives of plastic
surgery, endocrinology, urology, and gynecology
and obstetrics regularly attend the clinic. Since
the establishment of the gender identity clinic in
1966, there have been over 1200 inquiries by
mail or individual application of individuals who
considered themselves candidates for surgery. However, several of these applicants eliminated themselves from further consideration by failure to answer follow-up questionnaires about certain details
of their disorder. In the third year of its existence,
the clinic mailed additional questionnaires to all
applicants and has a waiting list of approximately
500 individuals who might be candidates for further
evaluation. It has never been the primary object
of the clinic to service all comers, but rather it has
been hoped that its principal objective would be a
mature and careful consideration of the problem,
especially of the relation of surgery to therapy.
Suitable patients are interviewed by a psychiatrist in a preliminary interview and if, on this
occasion, the various confusing disorders mentioned above can be tentatively eliminated, the
patient is then admitted for what is termed a fullscale evaluation. By this is meant an examination
by each of the various members of the gender
identity clinic during which time the patient is
given not only a physical examination but an extensive psychiatric and psychological work-up. Patients to be considered candidates for reconstructive
surgery must have fulfilled as a minimum the
following requirements:

1. Insofar as can be determined by the yarious psychiatric and psychological tests, the
patient must be a true transsexual and not
suffering from any of the allied disorders
mentioned above which have deviant sexual identification as part of the syndrome.
2. The patient must be at least 21 years of
age.
3. The patient must have no police record of
a serious crime or misdemeanor.
4. The patient must have lived in the female
sex role for a minimum period of twelve
months. During this time she must have
proved her ability to be gainfully employed
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5.
6.
7.

8.

as a female and to function satisfactorily
in society as a female .
The patient must be unmarried.
The patient must be available for follow-up.
A responsible member of the family , the
parents if possible, must be completely
aware of the situation and enthusiastically
support the possibility of surgical sex reassignment.
The patient must receive estrogen for a
minimum of twelve months prior to the
operative procedure.

It is obviously wrong, therefore, to think of
surgical sex reassignment as changing the sex of
the individual. The operation cannot be looked upon
as a sex change operation. It is simply one step in
the total rehabilitation of the patient. Since it is an
irreversible step, it is of the greatest importance
that no error be made in the diagnosis. Furthermore, it is highly desirable, but difficult of achievement, that the period of surgical sex reassignment
not be the final contact of the patient with the
clinic, so that the members of the clinic can be as
useful as possible in aiding the further rehabilitation of the patient in her continuing female sex role.
Results of Surgery. The postoperative behavior
and adjustment of transsexual patients is the key
to an evaluation of the role of surgery in the treatment of transsexualism.
The postoperative course of 17 male transsexuals who have had endocrine and surgical sex
reassignment has been the subject of a study by
Money and Ehrhardt of our clinic (Money and
Ehrhardt, 1970). These 17 patients were followed
from one to thirteen years. As a group, they expressed a willingness to undergo surgery again and
all of them considered that they had achieved
improved status. Eight of the patients had an
employment status which was essentially the same
as that before operation, but nine of the patients
had an improved employment and economic status.
Six of the patients, prior to the adoption of a policy
which would exclude such individuals at the present

time, had a police record. Two of these continued
to have difficulties with the police after surgery,
and it is for this reason that such patients are no
longer considered for surgery. The marriage status
of the individuals was as follows: two were married
preoperatively only as males, seven were married
postoperatively only as females, two were married
preoperatively as males and postoperatively as
females, and six were never married.
It seems clear that surgical reassignment does
not harm carefully selected patients, does offer
considerable improvement but, by the same token,
does not automatically result in the cure of various
problems not directly related to the problem of
gender identification.
Postoperative male transsexuals living as women do not lose the capacity for erotic genital sensation. Orgasm is not unusual. There seems to be a
particularly erotic area in the region of the prostate.
In general, follow-up of transsexual patients
who have been successfully operated on is difficult
because the more successful the treatment of the
patient, the less they wish to maintain contact with
the clinic and the more they wish to disappear into
the new society they have found and created.
Our experience would lead us to believe that
endocrine and surgical therapy of carefully selected
male transsexuals has a role in the contemporary
management of such individuals. However, it
cannot be overemphasized that the proper diagnosis
is not simple, requiring the dedicated cooperation
of psychiatrists and psychologists who are knowledgeable in the field and who are willing to devote
the necessary time and energy to add their skills
to those of the endocrinologists and surgeon; all
of whom as a team can make the only reasonable
approach to this problem.
REFERENCE
MONEY, J. AND EHRHARDT, A. A. Reassigned transsexuals :
marriage, employment, police records, psychotherapy, and
subjective satisfaction. Tenden zen der Sexualforschung.
Gunter Schmidt, Volkmar Sigusch, and Eberhard (eds.) .
Stuttgart: Ferdinand Enke, 1970, pp. 72-87.

Chemical Changes in Amniotic Fluid*
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The scope of my talk as represented by its title
encompasses a very large field which time does not
allow me to cover in its entirety. Therefore, I will
limit my remarks to one very specific area where
chemical changes in amniotic fluid could be used to
predict fetal maturity.
An ever present dilemma in modern obstetrical
management is the proper timing of delivery of the
fetus in situations where complications either threaten
its own life in utero or significantly affect maternal
morbidity. In such situations the obstetrician is confronted with the equivocal choice between premature
delivery and the high risk to the fetus of continued
intrauterine existence. In addition, he is placed in
a unique position where any sort of direct communication with one of his "patients," namely the fetus,
is nearly impossible. In the past, the delivery of
obstetrical care to the fetus and the monitoring of
its well-being were possible only through the agency
of the maternal organism. To improve upon this
situation, methods had to be found that would give
a more direct and accurate reflection of fetal status.
Hence, as complete a collection as possible of accurate indices relating to fetal maturity is of great
importance to the obstetrician. Some of the notable
complications of pregnancy in which these indices
would be of value are diabetes, toxemia, erythroblastosis fetalis, and previous poor obstetrical history: for example, cases requiring repeat cesarean
sections or abruptio placentae.
In the late fifties (Jeffccate and Scott, 1959), it
was recognized that the fetus contributed metabolic
products and secretions to the amniotic fluid, and this
encouraged many researchers to investigate a possible correlation between the status of the fetus and
the amniotic fluid constituents. At that time, however, the technique for amniocentesis had not been
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generally accepted, although it has been known
for over two decades, and the progress of research
was slow. With the acceptance of amniocentesis as
an aggressive means of diagnosis, the procedure for
withdrawal of amniotic fluid led to several investigations into fetal maturity indices. Amongst these
were the measurements of amniotic fluid creatinine
(Pitkin and Zwirek, 1967; Liley, 1961; Mandelbaum, et al, 1967), bilirubin (Droegemueller,
1969), and the examination of the cytology of cells
stained with Nile Blue Sulfate (Brosens and Gordon, 1966; Anderson and Griffiths, 1968). These
indices are now used in a fairly routine manner in
the management of obstetrical patients, and I shall
not go into any detail about them. A further and
more specialized offshoot of this research has been
the measurement of certain other specific amniotic
fluid constituents that might lead, in the near future,
to a more reliable picture of fetal well-being or
distress in addition to fetal maturity.
In spite of all the advances that have been made,
there still exists an appreciable degree of perinatal
mortality today, the major contributor being respiratory distress due to premature delivery. An estimated 25,000 newborn deaths annually in the United
States are attributed to this cause (Gluck, 1971).
The stage of fetal lung maturity at the time of delivery is of prime importance as it most often
entirely determines the survival or death of the neonate. For the neonate to survive, its lung has to
assume immediate function with the change from
an intra to an extrauterine environment. Thus, in
the case of a pregnancy complicated, for example,
by the presence of maternal diabetes or toxemia, the
obstetrician has to walk a tightrope where he must
maintain, to the best of his ability, a critical balance
between neonatal death due to respiratory distress
(hyaline membrane disease) and the threat of intrauterine demise caused by maternal disease. The
frustrating decision that has to be made is, "When
37
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is the earliest the obstetrician can deliver a healthy
baby that will survive?"
At the moment, what seems to be a ray of hope
on the horizon for the obstetrician has resulted from
research that was started in the early fifties on the
phospholipid content and its patterns in the fetal
lung. As early as 1929, von Neergaard (von Neergaard, 1929), demonstrated that surface forces contribute significantly to the retractive pressure of the.
lung. At that time he postulated a lung coating to
explain these observations. In 1955, Pattie (Pattie,
1955), showed that pulmonary edema foam contained some substance, or substances, that stabilized
the tiny bubbles seen characteristically in such foam,
and in 1957, Clements (Clements, 1957) and Avery
and Mead (Avery and Mead, 1959) identified a surface tension lowering substance in lung tissue. These
observations, subsequently confirmed by several
workers, led to the conclusive identification of this
surface tension lowering compound, called a surfactant, as being a,,B-dipalmitoyl lecithin.
l am now going to highlight some of the significant laboratory findings that have led us to
the point at which we are today. In 1961, Klaus
and his co-workers (Klaus, et al, 1961) showed
that bovine lung foam contained a mixture of several surface active compounds, the major constituent being dipalmitoyl lecithin. The other surface
active compounds he found were sphingomyelin,
phosphatidyl inositol, phosphatidyl dimethylethanolamine, and lysolecithin. The chemical structures
of some of these compounds are depicted in
Fig. 1. During the sixties, significant details of
the surfactant system were gleaned through the work
of Morgan (Morgan, et al, 1965), Fujiwara (Fujiwara, et al, 1968), and Gluck (Gluck, Kulovich,
et al, 1967, 1970) all working independently.
Morgan and his group worked on the identification
of the various components of the surface active
system in alveolar and whole lung homogenates in
the dog. They found that of the total lipids found
in dog lung, phospholipids constituted the major
group at 7 4.1 % . Of this group, phosphatidyl choline
was the major component. Phosphatidyl ethanolamine, lysophosphatidyl choline, which is lysolecithin, and sphingomyelin were also found, but in
much smaller quantities. These are all surface active
along with dipalmitoyl lecithin or phosphatidyl
choline, but phosphatidyl choline seems to be
by far the major component. As seen in Fig.
1, the lecithins are characterized by fatty acid groups
Ri and R 2 on the a and ,B positions of the triglyceride backbone. Fujiwara and his associates
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Fig. I-Chemical structures of some phospholipids.

(Fujiwara, et al, 1968) reported on the significance
of these fatty acids, which are normally C14 to C1s
fatty acids, and the total concentration of individual
phospholipids in the developing fetal lamb lung.
He took fetuses at three different ages of gestation; immature (99-119 days) , transitional (120134 days) and term (135-145 days) . Gestational
age in sheep is about 140 days. He found that
as gestation proceeded toward term, the amount
of phospholipids, both on a weight basis and
on a total phospholipid basis, increased. He also
found that phosphatidyl choline increased while
phosphatidyl ethanolamine decreased, and this will
be an important factor when we talk about the biosynthetic pathways. The significance of the fatty
acids was demonstrated by the observation that the
percentage of saturated fatty acids in the whole
molecule increased towards term, whereas the percentage of saturated fatty acids at the f3 position
stayed fairly constant. This means that now we have
two parameters by which the state of development
of the fetal lung can be assessed; in general, the
total amount of lecithin present and specifically, the
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amount of lecithin esterified with saturated fatty
acids. To test the hypothesis that lung maturity is
reflected by an increase in saturated lecithins, and
vice versa, Brumley and his colleagues measured
the surface tension and phospholipid content of
normal lungs and lungs from infants with respiratory distress syndrome (Brumley, et al, 1967).
Brumiey's data is shown in Table 1. As I men-

they parallel one another and coritiriue to do so
until about the 25th week of gestation where lecithin starts rising slightly more rapidly than. sphingomyelin. At about the 30th to 34th week there is
a sharp increase in lecithin concentration till term,
whereas sphingomyelin plateaus and starts going
dowrt again. The reason for this dramatic rise in
lecithin biosynthesis at about the 32nd to 34th week

TABLE 1
Phospholipid Analysis of Lung Tissue*

Condition
Infants with respiratory
distress
Infants recovered from
respiratory distress
Infants without respiratory
distress
Normal adults

Phospholipid
(mg/ g wet weight)

Phosphatidyl choline
(as % of total
phospholipid)

Saturated fatty acids
(as % in phdsphatidyl
choline)

10.4

46.4

64.7

17 . 4

56.9

70.4

3.0

22.3
16.8

58.8
45 .8

84.2
80.8

6.0
6.0

Surface Tension
(dynes / cm)
23

~ata adapted from Brumley, Hodson, and Avery, 1967.
tioned earlier, what the surfactant does is lower
surface tension and thus produce more elasticity
in the lung. in adults the surface tension of trachial
aspirates is somewhere of the order of 6 dynes/ cm.,
and the total phospholipid content is 16.8 mg/gm
wet weight. The content of phosphatidyl choline, as
a percentage of total phospholipids, is about 45.8%.
In the infant with no respiratory distress syndrome
these values are very close to those in the normal
adult. With respiratory distress syndrome the surface tension of trachial aspirates becomes much
higher. The amount of phospholipid is considerably
lower compared to that of adults and infants with
no respiratory distress syndrome, as are the amounts
of phosphatidyl choline and saturated fatty acid. As
the neonate recovers from the respiratory distress
situation, these values slowly start returning to
normal. This means that there is a valid justification
for implicating the amount of phospholipid, specifically phosphatidyl cholille, in the development of
fetal lung. Gluck and his group (Gluck, 1971;
Gluck, Kulovich, et al, 1967, 1970) reported
extensively in the middle and late sixties on the
biochemistry of surfactant production in the lung.
They measured the amount of dipalmatoyl lecithin
and sphingomyelin in amniotic fluid in humans
(Gluck, 1971), with the results shown in Fig. 2. Gluck
found that early in gestation, the amount of lecithin
is slightly lower than that of sphingomyelin but that

can be partially explained by the.picture of the biosynthetic pathways of these phosph9lipids (Fig. 3).
The lecithins are synthesized niainly by two .routes.
In pathway 1 (the ch9line incorporation pathway)
an a,,B-di-substituted d~glyceride reacts with cytidinediphospho choline (CDP-choline) thereby incorporating choline into the molecule which results in
phosphatidyl choline, or lecithin: In pathway 2 (the
methylatidn pathway) the a,,B-diglyceride incorporates
ethanolamine through the agency of cytidine-diphosphoethanolainine ( CDP-ethanolarriine) resulting in
phosphatidyl ethanolamine (PE) which by subsequent
methylations by S-adenosyltnethionine gives phos7
phatidyl methyl ethanolamine (PME) , phosphatidyl
dimethyl <;:thanolamine (PDME), and finally lecithin.
These two pathways need to be studied in greater
detail than they have been, but certain facets about
them are known. It has been shown that the dramatic
surge in lecithin at the 33rd to 34th week appears
because of the activation of pathway 1, that is, the
choline incorporation pathway. Gluck has evidence,
primarily clinical in nature, that the methylation
pathway is the primary mode of lecithin biosynthesis
in early gestation, but that on .or after about the 34th
week, the choline incorporation pathway becomes
the more important (Gluck, 1971). He found that
when he analyzed respiratory distress syndrome
cases in prematures, most of them were acidotic
and/or hypothermic. He also found that neither
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acidosis nor hypothermia were associated with
clinical respiratory distress syndrome in the full-term
infant. When trachial aspirates were obtained from
prenatal, or frbm premature infants while they were
still hypothermic, he found little or no phosphatidyl
dimethyl ethancilamine which meant that the inethylation pathway was not functioning. As the infants
were put into an incubator and temperature brought
up, increasing amounts of PDME were found in
trachial aspirates which indicated that the heat supplied to them was activating this pathway. These
findings suggested that the methylation pathway is
vulnerable to external insult. Yet if this were the case,
then some full-term infants should also show respiratory distress, which they do not. Gluck's explanation for this is based on his evidence that
early in gestation the methylation pathway is the
more important btit at about the 35th week the
choline incorporation pathway takes over causing the
surge of lecithin. As the choiine incorporation pathway is not vulnerable to external insult, it is producing sufficient quantities of surfactant for the
full-term infant not to have respiratory distress; Thus
the premature infant is at a disadvantage because
at around 30-34 weeks gestation when the methylation pathway is dominant and vulnerable to external
insult, the choline incorporation pathway has not
yet assumed maximal function, and hence, sufficient
surfactant is not being produced. The only lab finding that Gluck reports in support of his hypothesis
is that in vitro, the methylation pathway is markedly
inhibited below a pH of 7.2; in vivo, exposure to
cold or hypothermia or hypoxia causes acidosis in
the neonate, which could then inhibit the methylation pathway.
With all this data, we now have the basis for
developing a method for the prediction of re~
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Fig. 2-ConcentratiOns of sphingomyelin and lecithin in
amniotic fluid during gestation. (Reprinted with permission
from Gluck, Hosp. Pract. 6:45, 1971.)

spiratory distress in the neonate by measuring lecithin and sphingomyelin in amniotic fluid. Although
lecithin and sphingomyelin are measured individually, the results are reported in terms of the- ratio
of lecithin to sphirigomyelin. Once the ratio starts
getting higher than 1 or 2, one might be able to
give some indicatiori about whether respiratory
distress could be predicted in that fetus were it delivered at that time. The method we have developed
and are using at present is a modification of G!uck's
original method (Gluck, Kulovich, et al, 1971) and
is - outlined in Fig. 4. Three inililiters of amniotic
fluid are taken to which are added 3 ml of methanol
and 6 ml of chloroform in a centrifuge tube. The
whole is extracted once, centrifuged, and the lower

©
a,13-0iglyceride

@

CDP- choline

Phosphatidyl choline
(Lecithin)

CDP-ethanolamine

Phosphatidylethanolamine
_(PE)

Phosphatidyl methylethanolamine

Phosphatidyldiinethylethanolamine

(PME)

(PDME)

Fig. 3- Two postulated pathways for lecithin biosynthesis.
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3 ml Amniotic Fluid

l

3 ml Methanol
6 ml Chloroform

Extract once and centrifuge

i
i
i
i

Separate lower Chloroform: Methanol layer

Evaporate and reconstitute in 100 µl Chloroform

Transfer to Silica Gel H TLC Plate

i

Chromatograph in Chloroform-Methanol-Acetic Acid-0.93 aq. NaCl
70
:
25 : 4.8
3.2
a) Place chromatoplate in chamber saturated with iodine vapor
b) Remove chromatoplate from chamber, mark spots, wait for iodine to vaporize
c) Carefully scrape off the silica gel from marked areas

i

Measure phosphorous content by the method of Fiske & Subbarow (Fiske and Subbarow, 1925; King, 1938)

Fig. 4- Methodologic flow sheet.

chloroform methanol layer is removed , evaporated,
and reconstituted in 100 µ,l of chloroform . This is
then transferred to a thin-layer plate which is run in
the system, chloroform-methanol-acetic acid-0.9%
aq. NaO (70:25:4.8:3.2). We found this system to
be better than the old chloroform-methanoi-water
ones which are normally used for phospholipids:
Lecithin and sphingomyelin are visualized by placing
the thin-layer · plate in a chamber saturated with
iodine vapor. The iodine is deposited reversibly on
the areas where the lecithin and sphingomyelin are
located. The spots are then marked, scraped off, and
after the iodine has vaporized, the phosphorus
content of the spots is measured by a modification
of the Fiske and Subbarow method (Fiske and Subbarow, 1925; King, 1938). As one mole of phosphorus corresponds to one mole of lecithin and
sphingomyelin, by measuring the amount of phosphorus, we can calculate the absolute amounts of
lecithin and sphingomyelin and hence get the ratio
of one to the other. The test we have developed
takes an average technician approximately 3 hours
for 6 quantitative determinations. For a quick but
qualitative result, the test can be shortened by
eliminating the quantitative step, spraying the thinlayer plate with a phosphorus specific spray (Ditt-

mer and Lester, 1964) once it comes out of its
developing solvent system, and then estimating in
gross terms the amounts of lecithin and sphingomyelin by the visual intensities of their spots.
In our laboratory, we take a ratio of 2 or
greater tO predict fetal lung maturity. Gluck and his
group reported a few months ago that based on the
results of 302 amniocenteses from 272 pregnancies
using their method of monitoring ·the phospholipids,
not one single case of respiratory distress occurred
(Gluck, Kulovich, et al, 1971). Our experience
here at the Medical College of Virginia is of shorter
duration. After 49 complicated pregnancies which
we have monitored through 63 amniocenteses, we
have noi encountered any instance of respiratory
distress, and among these we have had four notable
cases : three of diabetes and one of Rh disease. The
Rh disease patient was delivered at 331/i weeks after
continuous monitoring of her lecithin-sphingomyelin
ratios, and she delivered a healthy viable infant whose
weight was compatible with dates. The three diabetics were delivered at 34, 35, and 36 weeks, and
all delivered healthy viable infants showing no signs
of respiratory distress.
Although the lecithin-sphingomyelin ratio seems
to be going a long way in alleviating the frustration
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of obstetricians, it should still be used with caution
because the volume of data is not sufficient to show
what would happen if one were to get a false positive, if one indeed ever gets false positives. The next
big step that needs to be taken is a detailed study
of the two major biosynthetic pathways for ledthin
and a study of the characteristics and properties of
the enzymes involved. If a compound could be
found to induce one or both of these enzymes, this
information would provide a much wanted tool in
the hands of an obstetrician or pediatrician for dealing with the fetus or neonate. Such information
would also be of great significance in cases of respiratory distress syndrome which are independent
of obstetrical management, such as premature labor.
In this instance, the physician is confronted with a
situation not of his own making and has to deal with
it as quickly and as best he can. At present, we are
able, with the use of the described test, to predict
the possibility of respiratory distress and thus have
the necessary facilities such as an incubator or a
respirator ready for the neonate immediately after
delivery. But of even greater benefit would be the
discovery of a compound drug which would induce
the choline incorporation pathway. This, as i
mentioned earlier, is insensitive to external insult,
and once biosynthesis of lecithin has been induced
by means of the pathway, the neonate itself can take
over the job it is supposed to do. A further goal
is the compiling of sufficient data such that a significant statistical analysis can be made concerning
the accuracy of predicting the severity of respiratory
distress associated with specific ranges of the
lecithin/ sphingomyelin ratio.
Finally, I would like to express my appreciation to our excellent housestaff who have been very
patient in supplying me with samples of amniotic
fluid as uncontaminated with blood as possible and
also my very deep gratitude to Dr. Dunn for his
constant and very enthusiastic encouragement of this
work.
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Hormonal Changes in Pregnancy*
MICHAEL E. YANNONE, M.D.
Visiting Professor of Biochemistry, Medical University of South
Carolina, Charleston, South Carolina; Professor of Obstetrics and
Gynecology, University of Iowa College of Medicine, Iowa City, Iowa

Because of the time factor involved, it would be
an impossible task to present the vast body of
biochemical information accumulated during the
last decade on the endocrine aspects of pregnancy.
However, certain key points can be made concerning
the feto-placental unit and the hormone levels and
effects in normal gestation. These concepts will be
discussed not merely for their academic value, but
also as a base to evaluate our present diagnostic
and therapeutic endeavors in obstetrical practice.
With the audience's indulgence, an occasional personal conjecture will be interjected concerning
hormonal mechanisms and clinical practices.
Feto-Placental Unit. The fetus and the placenta
are incomplete steroidogenic systems. They lack the
capability of synthesizing all necessary steroidal
hormones from more simple precursors in contrast
to the ovaries, testes, and adult adrenal cortex. To
complete the task a well-coordinated interdigitation
of the synthetic capabilities of fetus, placenta, and
mother is required. Since the mother is involved,
one wonders whether the term "feto-maternoplacental unit" would not be more appropriate.
First the fetal adrenal cortex and then the
placenta will be discussed; hopefully, emphasizing
the information which may have practical clinical
significance.
A. Adrenal Cortex. The fetal zone of the
adrenal cortex persists only during gestation, constitutes about 80% of the gland, and is active in
steroid metabolism. In the first trimester, it is
believed this zone is primarily stimulated by human
chorionic gonadotrophin (HCG); ACTH gaining
prominence in control thereafter.
The biochemical capabilities and limitations of
the fetal adrenal cortex are shown in Fig. 1. Utilizing

* Presented at the 43rd Annual McGuire Lecture Series,
December 3, 1971, at the Medical College of Virginia ,
Richmond.
MCV QUARTERLY 8(1): 43-51, 1972

acetate as a precursor, the fetal zone more readily
synthesizes the t::..5-3{3 hydroxysteroids pregnenolone and dehydroepiandrosterone (DHEA) than
the t::..4-3 ketosteroids such as cortisol and aldosterone. This is because of a relative block in 3{3hydroxy dehydrogenase and t::..5 isomerase activity.
Thus, the synthesis of large amounts of DHEA and
its sulfate is favored, and they are transported to the
placenta as such or after 16a-hydroxylation by the
fetal adrenal or liver. The placenta can metabolize
these androgens to estrogens as will be shown
shortly.
However, such a biosynthetic lack would
leave the fetus in jeopardy because of a cortisol and
aldosterone deficiency. This is rectified by the
fact that the fetal zone can utilize the readily
available placental progesterone to produce these
needed hormones. In fact, after the tenth week of
gestation, the increasing placental progesterone
secretion may enhance the 17,a, 21, and 11{3
hydroxylase capability of the fetal adrenal cortex
to produce the corticoids . Also, the ready passage of
maternal cortisol across the placenta is a secondary
protective mechanism.
B. Placenta. This endocrine organ is incapable
of synthesizing large quantities of progesterone and
estrogens from the simple precursor acetate. However, it can efficiently convert maternal plasma
cholesterol to progesterone as shown in Fig. 2. This
is clinically important for it means that an intact maternal-placental circulation will produce essentially
normal progesterone levels even though a fetal demise has occurred. The progesterone produced by the
placenta can be metabolized by the mother and fetus
to less active progestational metabolites or can be
utilized by the fetal adrenal as already described.
Since a 17 a-hydroxy lase deficiency in the placenta
precludes the conversion of progesterone to androgens and subsequently estrogens, another mechanism
must exist for placental estrogen synthesis.
43
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As depicted in Fig. 3, the placenta produces
estrogens from androgens of maternal and fetal
adrenal origin. Androstenedione, DHEA, and testosterone are converted by the placenta to estradiol
and estrone. It is estimated that the mother and
fetus each contribute about 50 % of the androgens
which are made into these 2 estrogens. Since the
ability to 16.a-hydroxylate androgens is essentially
limited to the fetal adrenal and liver, the fetus is
the major contributor of 16a-hydroxylated androstenedione, DHEA, and testosterone which are
converted by the placenta to estriol. The maternal
contribution to estriol at term is less than 10% and
probably arises from her adrenal androgens which
escape conversion to estradiol and estrone on passage
through the placenta to fetus. In the fetus, however,
her androgens can be hydroxylated at the 16a

position before recirculation back to the placenta
where synthesis to estriol can occur.
The above information indicates that the
clinical assay in pregnancy of plasma progesterone
or its major metabolite, pregnanediol, in the urine
would mirror placental integrity. On the other hand,
estrogen assays, particularly urinary estriol, would
reflect fetal integrity.
Hormone Secretion Patterns and Effects in Normal Gestation.
A. Progesterone. The corpus luteum appears
to be the initial source of progesterone in pregnancy. Subsequently, it is produced by the placenta
in increasing amounts from maternal cholesterol.
This transition of secretion from one gland to the
other is shown in Fig. 4. Both plasma 17a-hydroxy
progesterone and progesterone of corpus luteum

YAN NONE: HORMONAL CHANGES IN PREGNANCY

ACETATE - - - - + CHOLESTEROL

45

produces 200-300 mgms of progesterone daily. The
role of this large amount of hormone is not well
defined, but possible metabolic functions are:
1. The maintenance of growth and development
of the fetus; for example, it is a precursor
steroid for the synthesis of corticoids by the
fetal adrenal cortex.
2. An immunosuppressive agent to protect the
feta-placental homotransplant.
3. A defense mechanism acting on the myometrium to prevent premature expulsion of
the fetus.
4. Prepare the breasts for lactation.
5. Mediate a variety of biochemical events;
for example, antagonize at the renal tubule
the effects of the increased aldosterone concentration found in pregnancy.

20 a- o;hydropr09esleron•

Fig. 2-Principal precursors and metabolites of progesterone
in the human placenta. The m ajor steroid secreted by the
placenta (progesterone) is boxed in. (Reprinted with permission from Villee. New Eng. J. Med. 281 :473, 1969.)

origin are seen to peak at 3-4 weeks after ovulation. At 6-8 weeks post-ovulation, the progesterone reaches a nadir while the 17 a-hydroxy progesterone continues to decline. Since the placenta
lacks significant 17a:-hydroxylase capability, it is assumed that the secondary rise in progesterone reflects
placental function. It is of interest to note that
HCG-believed to maintain the corpus luteum of
pregnancy-continues to rise while both hormones
of corpus luteum origin are declining.
The secondary rise in placental progesterone
continues to increase progressively to a maximum
plateau at 36-40 weeks. This is seen from our data
in Fig. 5, where the level at 8 weeks of 2 micrograms % increases linearly to about 14 micrograms
% at term. The curve seems to parallel that of
placental weight and is of similar configuration to
that of urinary pregnanediol as depicted in Fig. 6.
It is important to note that no significant drop
in progesterone occurs prior to labor. However,
during parturition we and others have found a
slight downward trend of mean values and this may
be a reflection of placental ischemia secondary
to the uterine contractions. There is a rapid drop
in the plasma progesterone after delivery of the
placenta verifying the hormone's short half-life.
It has been estimated that the term placenta

B. The Estrogens. Quantitatively, estriol is the
major estrogen of human pregnancy. Its biologic
potency, however, is significantly less than that of
estradiol and estrone. The urinary excretion curve
for estriol is presented in Fig. 7; the amount rising
from low early levels to high levels at term. An
acceleration in the increase is apparent during the
last few weeks. There seems to be a good correlation between the estriol curve and that for the
fetal weight. Klapper, reviewing the literature, found
the average levels to be 10.1, 14.2, 19.8, and 26
mgms at 28, 32, 36, and 40 weeks respectively.
Similar curves for urinary estradiol and estrone
have been found, but the amounts are in the microgram range. These two estrogens, like estriol, probably reflect the status of the feta-placental unit.
Munson in our group has assayed unconjugated
estradiol in the plasma of normal · pregnancies. A
mean value of 200 nanograms % in early pregnancy
(9-16 weeks) rose to 1196 nanograms % during the last 8 weeks. A curve configuration similar to
urinary estrogen excretion patterns was obtained.
I suspect that the estrogenic effects of pregnancy are primarily due to estradiol, the most potent of these 3 estrogens. It mediates the growth and
function of the maternal reproductive organs and
probably is important to fetal growth and development. The reason for the large mass of estriol production is not clear. There is little evidence at the
moment that it is involved in the start of human
labor.
A biochemical effect of estrogen in pregnancy
or when given to a woman exogenously is the increased liver synthesis of certain steroid hormone
binding globulins. The increased hormone binding
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results in elevated concentrations of serum thyroxine (also the PBI), plasma cortisol, and testosterone. However, the amount of free or unbound
hormone, and presumably the biologically active
fraction, is unchanged. Unless this estrogen effect
is taken into account, the clinician can be misled
by the elevated laboratory result. The only exception to this physiologic change is for plasma cortisol
in pregnancy. The large amount of placental progesterone in pregnancy plasma competes with cortisol for binding sites on transcortin and increases
the free cortisol fraction. Therefore the pregnant
woman is actually in a state of mild adrenal hypercorticism.

C. Human Placental Lactogen (HPL). This
polypeptide hormone secreted by the syncitial
trophoblast is immunologically similar to but distinct
from human growth hormone. Metabolically it appears to be a weaker growth hormone. Its pattern
of secretion into the blood is shown in Fig. 8; the
increasing concentration throughout pregnancy
parallels the curve for placental weight. Like progesterone, its blood concentration reflects placental
rather than fetal integrity. Fetal death may not
significantly drop the level for a period of time as
long as the materno-placental circulation is intact.
The placental secretion is essentially unidirectional
into the mother; much lower levels being found in
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the fetus. The daily production can be as high as
400 mgms.
Possible roles of HPL are preparation of the
breasts for successful lactation and indirect growth
hormone effects. These include increased nitrogen
retention, increased maternal fatty acid utilization
sparing glucose for transmission to the fetus. The
fetus, like the adult brain, utilizes essentially glucose
only for its energy requirements. HPL is antagonistic
to insulin and as a consequence may be an important

factor in the diabetogenic effect of pregnancy.
D. Human Chorionic Gonadotrophin (HCG).
The blood and urine levels of this glycoprotein
secreted by the cytotrophoblast differ from the
curves seen for the previousiy discussed horomones
;md is shown in Fig. 9. The concentration in the
blood peaks at about 60 days, then decreases to
% to V:3 of the peak value throughout pregnancy
with a lower secondary rise at term.
Its role in pregnancy is not clear, but tradition-
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ally is believed to maintain the corpus luteum of
pregnancy. It may also regulate steroid secretion
by other glands; its possible ACTH effect on the
fetal adrenal cortex in early pregnancy has already
been mentioned.
Clinical Implications.
A. Progesterone and Pregnancy Status. Plasma
progesterone and urinary pregnanediol have been
measured in a variety of obstetric disorders to prognosticate dysfunction or to establish its presence.
Such diagnostic attempts have been less than satisfactory. Probably the primary reason for this is that
the hormone concentration can remain in the normal range even with fetal death as long as the uteroplacental circulation is intact. Other problems are
the wide day to day variation in the same individual
and the overlap of values in normal and abnormal
gestation. Even when the hormone concentration is
definitely subnormal, it is usually the effect of an
uncorrectable dysfunction rather than the cause.
Therefore exogenous progesterone substitution is
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generally of little value. Similar problems are encountered when serial assays for HPL are used
as a diagnostic tool.
B. Progesterone and Adequacy of the Corpus
Luteum; Abortion. Of probable clinical value are the
use of serial plasma progesterone or urinary pregnanediol assays to evaluate corpus luteum adequacy in certain types of infertility and possibly a
few cases of first trimester abortion. Although the
majority of such abortions are due to uncorrectable
causes such as chromqsomal defects, a few could
be due to corpus luteum dysfunction with disharmonious transition of steroid hormone production to

the placenta. When such corpus luteum inadequacy
is incriminated, correction of the infertility or prevention of another abortion may be achieved by
insuring an adequate corpus luteum. However, not
by the use of exogenous progesterone replacement,
but rather by the judicious use of ovulatory inductors such as Clomid® or the gonadotrophins to
insure normal follicular maturation which will result
in a normal corpus luteum.
C. Progesterone-Term and Premature Labor.
Elucidation of the mechanism which institutes labor
wou~d enhance our capability to induce labor for
medical or convenience reasons and to stop pre-
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mature labor. The theory most often advanced to
explain the mechanism which institutes parturition
is the progesterone-block concept. This maintains
that progesterone suppresses myometrial contractility
during gestation and labor begins upon withdrawal
of the hormone. However, our studies and those of
others have not shown a significant and consistent
drop in circulating progesterone prior to labor's
onset. These findings do not exclude a protective
role for progesterone as an effective decrease may
occur that is not apparent in the circulating levels.
One possibility that we investigated was that the
concentration of free and active progesterone decreased with advancing pregnancy because of increased protein binding of the hormone. However,
we found the percentage of binding to remain
constant throughout pregnancy, which meant that
as the total progesterone concentration rose so did
the concentration in the bound and unbound fractions. With this negative finding we have turned to
studies which may show decreased progesterone
levels within the myometrial cells. Our results are
·
too preliminary to draw conclusions.
In spite of our ignorance as to how labor starts,
we are not totally devoid of therapeutic agents. Within
reason labor can be induced at term with oxytocin.
It is much less effective earlier in pregnancy. Prostaglandins such as F2a appear to be effective at term
as well as earlier in gestation. However, on parenteral
use in the first 2 trimesters, the therapeutic-toxic
difference becomes too narrow. This problem may
be overcome by using the prostaglandin locally in
the vagina to induce an indicated abortion or
premature labor. Lastly, with judicious use of
intravenous alcohol in premature labor, the expulsion of the fetus can be delayed a few days to a
few months in about 65 % of the patients.
D. Estriol and Complicated Pregnancies. The
most important clinical consideration at the moment
is the value of serial estriol determinations in the
management of high-risk pregnancies. While it can
be helpful in certain complications of pregnancy such
as diabetes mellitus, toxemia, and dysmaturity to
evaluate the fetal status, it is not without pitfalls.
First the clinician is at the mercy of the quality
control of the laboratory doing his assays. Inaccurate
results can lead to false security or ill-timed termination of pregnancy. Even with a good laboratory,
the results may not always reflect the true status of
the pregnancy. Unfortunately, our knowledge of
estrogen metabolism in pregnancy is inadequate to
explain such discrepancies any better than it can
explain why Rh isO:.immunized jeopardized preg-
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nancies do not show subnormal estriol levels. Even
more disconcerting is the fact that excellent clinicians
using good laboratories are reporting perinatal
losses in diabetic pregnancies no better or even
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worse than reputable clinics have reported prior to
the availability of this assay. So far there has not
been any conclusive evidence that a marked
reduction in fetal mortality has been obtained because of estriol determination. In this light, the
overzealous utilization of estriol assays as a substitute for rather than an adjunct to clinical management is foolhardy .
As an adjunct to clinical judgment, the literature
seems to agree on certain helpful points. These
are as follows:
1. Significant day to day variation requires
serial assays to determine a mean for each
patient.
2. In a suspect pregnancy, weekly or biweekly
assays should be done from about the 30th
week up to the time of reasonable maturity
(about 34th week) at which time daily or
every other day determinations should be
carried out.
3. In any complicated pregnancy which is 34
weeks or beyond, any precipitous fall from
normal levels of urinary estriol and which
is verified over 2 or more consecutive days
dictates immediate delivery.
4. Chronic low estriol levels in preeclamptic
toxemia or dysmaturity do not necessitate
interruption unless there is a precipitous
drop from the low mean. Such babies left
in utero may not grow very much, but they
do achieve greater maturity.
5. Urinary estriol levels can be expected to
be low in mothers with anencephalic mon-

51

sters or on glucocorticoid therapy for medical reasons.
The development of new specific and sensitive
hormone assay methods and the increase in sophistication of metabolic studies has given us an impressive array of biochemical information concerning
the physiology and endocrinology of pregnancy.
However, the application of this knowledge to
the improvement of obstetrical care has been
difficult. This should not discourage us as medical
science must like the infant learn to crawl before
it can walk. Eventually we shall have all the facts
needed to obtain the obstetrical results that we
all desire. We have had a promising start.
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Uterine

Blood Flow During Pregnancy*

FRANK C. GREISS, JR., M.D.
Professor of Obstetrics and Gynecology, Bowman Gray School of
Medicine, Wake Forest University, Winston-Salem, North Carolina

Of those parameters pertinent to fetal wellbeing, the delivery of an adequate amount of blood
to the placenta seems to be the most crucial. At
our present state of understanding, uterine blood
flow (UBF) appears to be that parameter most often
affected by physiologic and pathologic conditions,
and it is certainly that factor most readily altered,
either favorably or unfavorably, by the physician.
In this presentation, normal changes in UBF during
pregnancy will be reviewed briefly, those factors influencing uterine and placental vascular dynamics
will be discussed, and the clinical relevance of these
ol?servations will be illustrated on the background
of varying levels of uteroplacental adequacy.
Homeostatic Changes in Uterine Blood Flow.
While our most comprehensive knowledge of UBF
changes during pregnancy has been determined in the
ewe, correlative data in subhuman primates and
women indicates that results are comparable, at
least during the last half of the gestation period
(Assali, Douglas, et al, 1953; Assali, Rauramo,
et al, 1960; Lees, et al, 1971; Metcalfe, et al, 1955;
Peterson and Behrman, 1969) . These changes are illustrated in Fig. 1. It can be seen that absolute UBF
increases most markedly during the period of most
rapid absolute fetal growth. Although fetal weight
tends to increase more rapidly than UBF, the proportion of UBF perfusing the placenta progressively
increases during this same time so that flow per unit
weight of fetus, placenta, and uterus remains essentially constant. Similarly, the amount of oxygen extracted from each milliliter of blood also remains
essentially constant (Huckabee, et al, 1961) indicating that the increase in placental blood flow is
matching the increasing demands of the fetoplacental

* Presented at the 43rd Annual McGuire Lecture Series, December 3, 1971 , at the Medical College of Virginia,
Richmond. (This investigation was supported by United
States Public Health Service Grant No. HE-03941-12 from
the National Heart Institute.)
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Fig. I- Derived graph of relative and absolute uterine blood
flows, fetal. weight and proportionate placental blood flow
during ovine pregnancy (Barcroft, 1947; Greiss and Anderson,
1970; Huckabee, et al, 1961; Makowski, et al, 1968). During the
last half of gestation, relative uterine blood flow is constant,
and the proportion of uterine blood flow reaching the placenta
progressively increases.

unit. After term gestation, however, available information indicates that placental blood flow decreases
relative to fetoplacental requirements (Dixon, et al,
1963), blood oxygen extraction increases and fetal
well-being is progressively compromised. Similarly,
placental blood flow is reduced in patients with essential hypertension, chronic renal disease, preeclampsia or eclampsia, twin gestation and premature
labors complicated by abnormal bleeding or infection (Browne and Veall, 1953; Dixon, et al, 1963;
Johnston and Clayton, 1957; Landesman and
Knapp, 1960; Morris, et al, 1955; Weis, et al,
1958). The severity of the reduction in flow with
toxemia of pregnancy seems directly related to the
severity of the disease process.
Dynamic Control of Placental Blood Flow. A
schematic representation of those factors affecting
placental and non-placental blood flow in the uterus is
shown in Fig. 2. At term gestation in women, the proportion of total UBF perfusing the placenta probably
exceeds 85 percent (Lees, et al, 1971; Makowski,
MCV QUARTERLY 8(1): 52-60, r972
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et al, 1968). Therefore, our primary attention should be directed to the second part of the
equation accompanying the illustration. This shows
that placental blood flow varies directly with the perfusion pressure (UABP-IUP-UVBP) and inversely
with the resistance of the spiral arterioles supplying
the intervillous space (Ripr) and the resistance imparted to the blood vessels as they course through
the myometrium (Re). The effects of various stimuli
on these resistances are summarized in Table I. All
vasodilator stimuli exert inconsequential or no effect
while all vasoconstrictor stimuli are capable of producing marked persistent reductions in flow. Four
observations are of particular pertinence to the
clinician: 1) Under normal circumstances, the placental vasculature approaches maximal vasodilatation (Greiss, 1966). This means that we have no effective way of further increasing placental blood
flow. It also means that placental perfusion will vary
directly with and in proportion to changes in systemic blood pressuret (Fig. 3), that is, a 30% decrease in systemic blood pressure will cause a 30%
decrease in placental blood flow. 2) Endogenous or
exogenous vasopressor hormones or drugs (Fig. 4)

Amniotic
Cavity

and sympathetic nerve stimulation (Fig. 5) cause
significant vasoconstriction (increase R;pL) usually
proportionately greater than that induced in other
peripheral vascular beds. This means that although
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Fig. 2- Schematic representation of those factors determining
placental and non-placental uterine blood flow. Note that the
reactivity of the non-placental vasculature (R •N- PL) is different
from that of the placental vasculature (R,PL), the extrinsic
vascular resistance (R0 ) imparted by contracting myometrium
affects both vasculatures similarly, and that by increasing intrauterine and intervillous space pressures, myometrial contractions
decrease placental perfusion pressure. UABP and UVBP
indicate uterine arterial and venous pressures, and IUP equals
intrauterine (intra-amniotic) pressure.
t For practical purposes in the absence of uterine contractions, perfusion pressure is determined primarily by arterial blood pressure.
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Fig. 3- Graph of the relationship between perfusion pressure
and uterine blood flow at term gestation in the ewe indicating
that the dominant placental vasculature is almost maximally
dilated and that placental perfusion decreases linearly with
decreases in the systemic blood pressure. (Reprinted with
permission from Greiss. Am. J. Obstet. Gynec. 96: 41, 1966.)
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Fig. 4-0riginal tracing of the effect of norepinephrine on
uterine blood flow in the gravid ewe. Circled numbers indicate
uterine conductance values. Such profound vasoconstriction
and decrease in uterine blood flow is typical of the action of
endogenous adrenal medullary hormones and peripherally
acting vasopressor agents. (Reprinted with permission from
Greiss. Am. J. Obstet. Gynec. 112: 20, 1972.)
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TABLE 1
Responses of the Uterine Vasculature During Pregnancy
Vasoconstriction
Demonstrated to be
Effective

Vasodilatation

1. Alpha adrenergic stimulation
(epinephrine, norepinephrine)
2. Sympathomimetic Agents2
(vasopressor drugs)
3. Sympathetic nerve stimulation 3
(adrenergic)
4. Myometrial contractions4
5. Hypoxemia, severe•

1. Acetylcholine and parasympathomimetic agents6
(minimal, transient)
2. Nitroglycerine (mild, transient)'

1

3. Estrogens (site of dilatation undetermined)B

1. Ischemia*'
2. Hypoxemia, mild* 10
3. Beta adrenergic stimulation* 11
(isoproterenol, epinephrine)
4. Sympathetic nerve stimulation12
(cholinergic)
5. Parasympathetic nerve stimulation1'

Demonstrated to be
Ineffective

* Indicates responses

different from those in the non-pregnant uterus.

Ahlquist, 1950; Greiss and Pick, 1964
Ahlquist, 1950; Greiss and Van Wilkes, 1964
a Greiss and Gobble, 1967
4 Ahlquist, 1950; Borrell, et al, 1964; Greiss and Anderson, 1968; Lees, et al, 1971; Ramsey, et al, 1963
' Boba, et al, 1966
6 Ahlquist, 1950; Greiss, Gobble, et al, 1967
' Greiss, 1970
s Greiss and Marston, 1965
• Greiss, 1966
10 Greiss, Anderson, and King (in press)
11 Greiss, 1972; Greiss and Pick, 1964
12 Greiss and Gobble, 1967
1a Greiss, Gobble, et al, 1967
1

2

perfusion pressure will be increased by such stimuli,
the degree of placental vasoconstriction will be so
great as to cause a net decrease in placental perfusion. 3) Myometrial contractions reduce placental
blood flow by constricting arteries as they course
through the myometrium (increase R e) and by increasing intervillous space pressure which in turn decreases the perfusion pressure. Since the pressure in
the intervillous space is the same as that in the
amniotic cavity (Schwarcz, et al, 1967), placental
blood flow will vary inversely as the intra-amniotic
(intrauterine) pressure (Fig. 6). This means that
during an individual contraction, placental perfusion
will vary inversely with the intensity and duration of
the contraction and over a given time interval, mean
flow to the placenta will be determined by the frequency of contractions as well. 4) Since gravid UBF
cannot be practically increased by the physician and
since almost every stimulus potentially detrimental to
placental perfusion is effective, the physician's role
becomes one of recognizing and minimizing detri-

mental effects when they may be critical to fetal
survival.
Clinical Applications of Uterine Vascular
Dynamics. A hypothetical relationship between the
adequacy of placental perfusion and the condition of
the fetus is described in Fig. 7. While the percentages
of optimal placental blood flow are educated guesse~
(Greiss, unpublished observations; Hess and Hon,
1960), they cannot be considered actual and serve
only as reference points to illustrate the effects of
clinical conditions upon placental perfusion and the
fetus. Four zones of fetal status are described; two
compatible with prolonged but not necessarily optimal
fetal growth and development, one permissive of
short-term survival during progressive fetal deterioration, and one incompatible with life for more than
ten or fifteen minutes. These zones are defined by the
mean flow during a fixed period of time, but within
an observed time interval, transient reductions or
complete cessation of placental blood flow may occur. Such reductions are most frequently related to
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Fig. 5- 0riginal tracings of the effect of lumbar sympathetic nerve stimulation on uterine blood flow in the pregnant ewe. Although
sympathetic tonus is low during resting condition~, profound uterine vasoconstriction is evoked by maternal hemorrhage. (Reprinted
with permission from Greiss and Gobble. Am. J. Obstet. Gynec. 97 : 962, 1967.)

uterine contractions (Borr~ll, et al, 19~4; Ramsey,
et al, 1963). Under optimal conditions, br.ief episodes of intervillous stasis evoke no evidence of fetal
distress. However, when such episodes are superimposed upon a fetoplacental unit already co!llpromised
with respect to placental perfusion, fetal hypoxia
will be manifested ·ini'tially by late d~celer'ation of the
fetal heart rate with respect to uterine contractions,
later by progressive fetal acidosis and finally by persistent bradycardia signaling incipient fetal demise
(Hon and Quilligan, 1968) .
Labor. During strong myometrial contractions,
placental perfusion temporarily ceases. For illustrative purposes, let us assume that intervillous flow
stops for 30 seconds of a 45 second contraction and
45 seconds of a 60 second contraction. The effects
of such contractions on mean placental blood flow
are illustrated In ~ig. 8. As the quration and frequency of myometrial contractions increase, mean
placental flow progressively decreases. If labor

begins when placental flow is optimal, even the most
active contractions (solid line) cause no fetal jeopardy. However, when flow is suboptimal initially,
active labor will evoke fetal distress (long dashed
line) and when the pre-labor flow is borderline, even
mild labor will cause distress or fetal death (short
dasheq line). It is evident, therefore, that labor is
inherently stressful to the fetus. This fact must be
remembered whenever patients with high-risk pregnancies begin spontaneous or induced labor.
Hemorrhage. Maternal hemorrhage is a most
potent stimulus of adrenal medullary hormone secretion and sympathetic nerve stimulation. Acute moderate hemorrhage (500c....750 ml. within 15 minutes)
causes minimal changes in maternal blood pressure
and pulse rate. However, these parameters are
maintained by peripheral vasoconstriction with an
inevitable decrease in placental blood flow (Fig. 9).
Acute severe hemorrhage ( 1500 ml. in 15 minutes)
evokes a further increase in peripheral and uterine

GREISS: ~TERINE BLOOD FLOW DURING PREGNANCY

56
RttESUS 66-2
TERM PREGNANCY

20
15
10

UBF
cc/min

MATERNAL
B.P.

mm Hg

IUP
mm Hg

·5
0
127
85
42

0

45- ·
30
15
o -.:?=~~~~~~"~~~~~--~~~~~
0
5
10
15
20
25

30

35

40

Minutes

Fig. 6---0riginal tracing of the effect of spontaneous uterine contractions on uterine blood flow in the term-pregnant Rhesus monkey
The uterine blood flow trace is the inverse image of the intrauterine pressure pattern. Uterine blood flow achieves maximum levels
during myometrial diastole only. Therefore, mean uterine blood flow will decrease as the frequency of contractions increases and
the duration of myometrial diastole decreases. (Reprinted with permission from Greiss and Anderson. C/in. Obstet. Gynec. 11: 96,
1968.)
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Fig. 7- }Iypothetical relationship between placental blood flow and the status of the fetus. Of the many parameters determining
fetal well-being, placental blood flow is the most variable and the parameter most subject to pathologic change·. The significance of
detrimental influences on placental blood flow increases as the pre-stress level of flow decreases.

vasoconstriction with an associated decrease in systemic blOod pressure. Together, these two factors
cause a marked decrease in placental perfusion
( Greiss, 1966). Figure 9 shows that acute severe
hemorrhage may rapidly compromise the fetus even
when the pre-hemorrhage status of placental per-

fusion is optimal. At slower rates of blood loss, the
degree of peripheral vasoconstriction necessary to
maintain maternal integrity will be less because of
compensatory shifts of body fluids into the vascular
compartment, and placental perfusion will not be reduced so drastically. Therapy for blood loss should

....
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Hypothetical Relationship Between
Fetal Condition and Placental Blood Flow
LABOR

Optimal

~=frequency (min) O
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~.
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Fig. 8-Effect of uterine contractions on mean placental blood flow. As the duration and frequency of contractions increase, mean
flow progressively decreases. If labor begins with optimal blood flow, placental perfusion is more than adequate even during very
active contractions (solid line). However, if placental perfusion is borderline before labor such as occurs with toxemia, even mild
contractions may cause fetal distress or demise (short dashed line).

be directed toward correcting the vascular volumecapacity discrepancy. Optimally, this should be accomplished with whole blood: However, in emergency
situations when blood is not available or is being
readied, rapid intravenous infusions of salt solutions
or blood substitutes will still improve placental perfusion significantly (Boba, et al, 1966).
Non-hemorrhagic Hypotension. Except for
hemorrhagic and septic shock, most circumstances
that decrease maternal blood pressure do not change
placental vascular resistance. Therefore, placental
blood flow will decrease in proportion to the degree
of hypotension. Such circumstances occur most frequently following spinal anesthesia for cesarean section. The effects of a typical clinical situation on
placental blood flow are illustrated in Fig. 10. It
should be evident that only those fetuses in the

suboptimal environment prior to anesthesia will be
in jeopardy and only those in the lower suboptimal
range may die. This is especially true since hypotension of this severity is usually corrected promptly.
Generally, hypotension will respond to a combination
of left-uterine displacement and a rapid intravenous
infusion of 500-1000 ml. of salt or dextrose solution
( Greiss and Crandell, 1965). The former relieves
pressure on the inferior vena cava, thus increasing
venous return to the heart and cardiac output. The latter reduces the vascular volume-capacity disparity induced by sympathetic nerve paralysis and peripheral
vasodilatation. However, some patients do not respond to these techniques, and vasopressor therapy
becomes necessary. At this point, a knowledge of the
vasomotor control of the placental blood vessels is
requisite for the selection of that vasopressor agent
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Hypothetical Relationship Between
Fetal Condition and Placental Blood Flow
ACUTE HEMORRHAGE
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Fig. 9- Effect of acute sudden hemorrhage on placental blood flow in the ewe. Prompt therapy with whole blood or blood volume
expanders is necessary to protect the fetus even if pre-hemorrhage conditions were optimal.

most beneficial to placental perfusion. The effects of
two agents, ephedrine and metaraminoP, on placental blood flow are depicted in Fig. 10 (Jam es,
et al, 1970). By acting primarily on the heart
with minimal uterine and peripheral vasoconstriction, ephedrine accomplishes the greatest improvement in placental blood flow. Metaraminol
improves maternal blood pressure by acting in roughly
equal amounts on the heart and peripheral blood
vessels. Therefore, the beneficial effect of improved
blood pressure is partially offset by placental vasoconstriction so that the fetal environment is improved
less effectively. The difference between the two agents
becomes significant when one considers flow responses
in a fetus with initial borderline placental perfusion
(short dashed line, Fig. 10) . Ephedrine therapy improved perfusion sufficiently to produce a live although probably depressed infant while metaraminol
t

Aramine®, Merck Sharp & Dohme

therapy was inadequate to accomplish even this outcome. Not shown in Fig. 10 are the effects of primarily peripherally acting pressor agents such as
phenylephi;ine. * Such agents cause so much placental
vasoconstriction that despite restoration of normal
blood pressure, placental perfusion is not improved
and may even decrease further (Greiss and Crandell,
1965).
The above illustrations depict the effects of individual co.nditions upon placental blood flow . In
clinical practice, it should be evident that such conditions may occur concomitantly, and actually there
is a positive tendency for this to happen. Therefore,
placental perfusion is often reduced by multiple
factors. Our ability to minimize the effect of these
factors on the. fetal environment may make the difference between a healthy child and a stillborn or
retarded infant.

* Neo-Synephrine®, Winthrop Labs.
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Hypothetical Relationship Between
Fetal Condition and Placental Blood FI ow
SPINAL HYPOTENSION 8 ITS THERAPY

Prespinal
B.P. 120/60

Spinal Hypotension
B.P 70140

Ephedrine (heavy line) vs.
Metarominol (light line)theropy
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Fig. 10--Effect of hypotension induced by spinal anesthesia on placental perfusion. Only those fetuses with initial suboptimal
placental blood flow will be affected by marked hypotension (dashed lines). If vasopressor therapy is required, appropriate selection
of the drug according to its mode of action may be crucial to fetal survival.
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Placental Circulation*
ELIZABETH M. RAMSEY, M.D.
Visiting Professor of Obstetrics and Gynecology, University of Virginia
School of Medicine, Charlottesville, Virginia

One of the most important developments of
recent years in the field of uterine physiology has
been the recognition that the endometrial changes
occurring during the menstrual cycle and those
associated with pregnancy are interlocking, sequential events in an ordered progression from the first
day of the cycle to parturition-and not separate
phenomena as was formerly believed. No component of the endometrium illustrates this progression more strikingly than does the vasculature.
Much of the story of uterine vascular pattern
and circulatory mechanism is based upon studies
in the rhesus monkey, employing in vivo techniques
inapplicable to clinical patients. (These studies
were carried out in the Department of Embryology,
Carnegie Institution of Washington at Baltimore.)
Subsequent checking of the monkey findings against
their human counterparts, in operative and necropsy
specimens, etc., has shown the monkey to be a
valid experimental model with reproductive system anatomy and physiology closely similar to the
human (Ramsey and Harris, 1966).
Following the menstrual slough the vasculature
regenerates pari passu with the endometrial stroma
and glands (Fig. 1). Initially a long capillary network forms between the stumps of spiral arteries in
the basalis and the epithelial surface. Subsequently,
muscular and elastic layers forming around the capillaries transform them into true arteries. It may be
noted parenthetically that this is a more accurate
description than the familiar statement that "spiral
arteries grow toward the endometrial surface." A
rich capillary bed remains in the immediately subepithelial layer and connects the arteries with veins
which run perpendicularly toward the myometrium.
Although the follicular phase of the cycle is
frequently referred to as the "growth phase,"
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growth of spiral arteries continues unabated during
the corpus luteum phase and even further on, as
we will see. Indeed, vascular growth during the
lutein phase outstrips stromal growth, so that the
increasing length of the arteries must be accomodated within the endometrium by ever increasing
coiling (Fig. 1 ) .

Fig. 1-Camera lucida drawings of the vascular bed at three
stages of the menstrual cycle in the rhesus monkey. Left.
postmenstrual; Center. postovulatory; Right. late secretory.
Myometrium stippled. (Reprinted with permission from
Bartelmez. Contrib. Embryo/. 36: 153-182, 1957.)

The implanting ovum achieves its first contact
with the maternal blood supply when the penetrating
trophoblast both taps and engulfs capillaries of the
subepithelial network (Fig. 2) , permitting maternal
blood to seep, under very low pressure, into the
61
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Fig. 2- Photomicrograph of an early human implantation. (a) trophoblastic lacunae; (b) maternal capillaries. Carnegie Collection
8004, 7th day of pregnancy, section 11-4-4. (Reprinted with permission from Hertig and Rock. Contrib. Embryo/. 31: 65-84, 1945.)

lacunae of the trophoblastic shell. With progressive
penetration by trophoblast, the terminal tips of
spiral arteries are opened up and maternal arterial
blood flows into the shell. This meanwhile has
itself been enlarged and transformed by the development of chorionic villi (Fig. 3) . It is around the
villi, in the inter-villous space, that the maternal
blood now flows and from now on we may speak
of a placenta and placental circulation.
Reconstructions of representative uteroplacental arteries, both human and monkey, at comparable
stages of gestation (Fig. 4), show that there is
very little qualitative change in growth pattern during
the first weeks after implantation (Harris and Ramsey, 1966; Ramsey, 1949) . The coiling of the
arteries continues and there is just a slight indication of a new process at the arterial tips where
trophoblast is beginning to replace normal wall
structure. Soon however a change does become
manifest. Arterial elongation (as determined by

careful micromeasurements) is continuing, but the
thickness of the endometrium is being diminished
as the result of trophoblastic erosion combined with
pressure of the overlying conceptus. Thus, the
previously vertical arterial stems are diverted toward
the margins of the implantation site, an increasingly
sharp angulation developing. With the continuation
of these processes in succeeding weeks, the increased coiling of the artery is no longer sufficient
to effect its accomodation in the thinned endometrium, so back and forth and lateral looping is
added. A terminal dilatation of the artery develops proximal to its point of entry into the intervil1ous space.
At about midpregnancy when, as Reynolds
has shown (Reynolds, 1947), the enlargement
of the uterus by growth of its parts gives place to
enlargement by stretching, the coils of the arteries are "paid out," as coils of rope on the deck
of a ship are paid out when the space between ship
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Fig. 3-Photomicrograph of a portion of a monkey placenta
in situ. Chorionic plate above; entrance of an endometrial
spiral artery into the intervillous space at the left. Carnegie
Collection C-477, 29ih day of pregnancy, section 47b.

and anchorage is increased. The coils are more
fully smoothed away in the monkey than in man,
probably becaus.e monkey endometrium undergoes
the greater stretching.
The terminal dilatations of arteries communicating with the interviUous space appear to be
the result of the weakening of the vessel wall
brought about by replacement of muscle and
elastic tissue by trophoblast. Appearing first as an
intraluminal accumulation (Fig. Sa), the trophoblastic cells gradually invade and replace the
vessel wall (Fig. Sb). The invasion is earlier in
the monkey and baboon than ih the human, but it
is deeper and more extensive in the latter. Human
cytotrophoblast penetrates the endometrial stroma
as well as entering the arterial lumen and invasion
of the wall proceeds from without as well as from
within (Fig. 6). The more drastic elimination of
normal vascular wall resistance in man doubtless
occasions the larger and more persistent terminal
dilatations of human uteroplacental arteries. A
further result of greater trophoblastic activity in
the human is the erosion of arteries all the way
to the midendometrium where branches arise from
the main spiral stems. These branches then com-

municate with the intervillous space which explains why there is a proportionately greater number of arterial entries in humans than in monkeys.
Upon occasion the trophoblastic action, in contrary fashion, may cause occlusion of branches
or even main arterial stems.
Venous drainage, at all stages of the reproductive cycle, is a less dynamic affair than arterial
inflow. The basic venous pattern in the endometrium is a grid with dilatations into venous lakes
at the junction of vertical and lateral limbs. These
relationships continue into pregnancy with certain
of the vertical channels increasingly distended as
they are required to accommodate the ever increasing volume of placental blood. Other channels
are passively obliterated by external compress10n.
On the physiological side there is again continuity between prepregnant and pregnant states.
From the standpoint of circulation, this is most
apparent in the persistence of an intrinsic contractile potential in the spiral arteries. This is
manifested during the menstrual cycle by isolated
contractions at the myoendometrial junction which
produce ischemia leading to foci of endometrial
necrosis and slough (Bartelmez, 19S7), and in
pregnancy by intermittency of flow through individual spiral arteries into the intervillous space
(Martin, McGaughey, et al, 1964).
The opposite number to uteroplacental circulation is of course fetoplacental circulation. Propelled by the vis a tergo bf fetal blood pressure,
fetal blood courses through the umbilical arteries
into the subdivisions which run laterally through
the chorionic plate. Finally, the vessels dip into the
substance of the placenta and travel through the
arborizations of the fetal villous tree. They proceed in comparable subdivisions to the terminal
villi. There the fetal capillary bed, coming into its
closest proximity to maternal blood in the intervillous space, forms the ultimate area of maternalfetal exchange. Oxygenated blood returns via vessels running through the same villous stems to the
umbilical vein and thence to the fetal body (Martin
and Ramsey, 1970).
The mechanism of circulation within the placenta, first hypothesized upon the basis of anatomical data, has been established by radioangiographic studies (Donner, et al, 1963). Especially
with cirieradioangiography, it is possible to visualize
directly the inflow of arterial blood to the intervillous
space (Fig. 7) , its circulation through the space, and
finally its drainage back to uterine veins.
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Fig. 4-Diagrammatic representations of the course and configuration of the uteroplacental arteries in the rhesus monkey and man,
at comparable stages of gestation. (Reprinted with permission from Harris and Ramsey. Contrib. Embryo/. 38 : 43-58, r9~6.)

The propulsive force throughout is the head
of maternal blood pressure which drives blood
into the intervillous space in discreet, fountainlike
"spurts." The incoming blood wafts aside the villi
surrounding the orifices of entry, but once the

propulsive force is reduced, in part by the, baffie
action of the villi, the b.lood disperses laterally crowding the existing content of blood through the venous orifices in the basal plate into the ' uterine
drainage channels (Fig. 8). During uterine con-
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Fig. Sa-Photomicrograph of uteroplacental arteries in the
monkey illustrating early accumulation of trophoblast within
the lumen of the artery. Carnegie Collection C-477, 29th
day of pregnancy. (Reprinted with permission from Wislocki
and Streeter. Contrib. Embryo/. 27: 1-66, 1938.) ·

Fig. 6-Photomicrograph of a human uteroplacental artery
showing replacement of wall and penetration of stroma by
trophoblast. Carnegie Collection 10117, 8Sth day of pregnancy. (Reprinted with permission from Ramsey. Prenatal
Life. Wayne State University Press, 1970, pp. 37-S3.)

Fig. Sb-Photomicrograph of uteroplacental arteries in
monkey illustrating subsequent replacement of the arterial
wall without trophoblastic penetration of stroma. Carnegie
Collection C-629, S3rd day of pregnancy. (Reprinted with
permission from Ramsey. Contrib. Embryo/. 33: 113- 147,
1949.)

tractions both inflow and outflow cease, in whole
or in part, depending upon the strength of the contraction (Ramsey, Martin, McGaughey, et al, 1966) .
The volume of the placental pool, however, is maintained. That is to say, the old concept that "contractions squeeze the placenta like a sponge" is incorrect; rather blood is trapped in the placenta during
contractions.
Radioangiography of the fetal side of placental
circulation (Martin, Ramsey, and Donner, 1966)

shows the progress of blood from the fetal body into
the capillary network of the fetal cotyledons and
back via the umbilical vein. Double injection of a
radiopaque medium (Ramsey, Martin, and Donner, 1967), that is, into fetal and maternal circulations in rapid succession, permits visualization of the
1 : 1 relationship between maternal spiral arteries
and fetal cotyledons (Fig. 9) .
Two points of clinical interest emerge from the
foregoing. The first is that placental circulation
ceases during strong contractions. That this may
present the fetus with periods of anoxia is clear and
should contractions be unduly prolonged, as the
result of pathology or medication, it could indeed
be critical. Second, and somewhat mitigating the
implied threat of the cessation of flow, is the fact
that the pool of placental blood is preserved
throughout. Thus, under normal conditions, continued maternal-fetal exchange is made possible.
And that exchange, of course, is the whole
purpose of the long and elaborate procession of
vascular changes from Day 1 of the menstrual cycle
to parturition.
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Fig. 7-Photographs of X rays made at 2, 3, and 77\l seconds respectively after injection of contrast material into a femoral artery
of a monkey. (R.a.) renal artery ; (S.a.) endometrial spiral artery;- >''spurts" into intervillous space. Carnegie Collection Monkey
60 / 14, lOOth day of pregn~ncy. (Reprinted with permission from Ramsey, et al. Montanino Editore, Napoli. II: 1779-1784, 1962.)

Fig. 8-Composite drawing of the primate placenta to show its structure and circulation. (Drawing by Ranice Davis Crosby for
E. M. Ramsey. Courtesy of the Carnegie Institution of Washington.)
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Fig. 9- Spot films made during a combined fetal and maternal injection study. (A) taken 3 seconds after injection of contrast
material into the fetal circulation; (B) taken 2 seconds after immediately subsequent maternal injection. (FC) fetal cotyledon;
(SA) endometrial spiral artery ;- >''spurts" into the intervillous space. Carnegie Collection Monkey 65 / 80, 152nd day of pregnancy.
(Reprinted with permission from Ramsey, et al. Am. J. Obstet. Gynec. 98: 419-423, 1967.)
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Electronic Monitoring of the Fetus*
S. EDWARD DAVIS, Ill, M.D.
Assistant Professor of Obstetrics and Gynecology,
Medical College of Virginia, Richmond, Virginia

Although the fetal electrocardiograph ( FECG) ,
was recorded earlier in this century, utilization of
the electrical activity of the heart for fetal assessment is really a procedure of approximately the
last two decades. This has come about primarily
through the work of Dr. Ed Hon in Southern
California and Dr. Roberto Caldeyro-Barcia in
Montevideo. Early attempts to obtain signals were
made from the maternal abdomen, but they were
frustrated by problems · of noise either from the
maternal heart or from the muscles of the abdominal wall. The advantages of working in the
vagina-it strikes me as strange that this should
take so long to occur to an obstetrician-is an insight of the last decade, resulting in the placement
of an electrode on the fetal scalp, rather than on
the maternal abdomen, with a vast improvement
in the signal-to-noise ratio and reliability. At the
present time, the main use of the electrical activity
of the heart obtained through such an electrode
is to drive a heart rate-sensing device to give the
fetal heart rate which is then used to indicate fetal
status. Much speculation has been made as to
whether or not the FECG is a more sensitive indicator of fetal status than the heart rate, but that
question is unresolved, and there is certainly a
good deal of evidence to indicate that such is not
the case. The fetal electrocardiograph obtained
from the maternal abdomen can be used to detect
fetal life, multiple pregnancies, and it can be extracted from the background noise by means of
computer averaging techniques in order to study
the electrical signal itself.
The concept utilized in electronic monitoring
of the fetus is that the application of a stress to the
organism in question (feto-placental unit) will produce a response which allows assessment of status
prior to the production of permanent damage. For-
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tunately, there is a physiologic situation in which
there is stress to the organism-namely labor. The
steady-state of exchange across the placenta, which
characterizes pregnancy and is adequate to allow
not only survival of the fetus but also growth, is
normally terminated by labor, a process which deletes
part of the time available for exchange. Through the
work of Dr. Hon, studies of the implication of fetal
heart rate changes observed during labor became
much clearer.
It has been pointed out that much of the
methodology used in medicine at present is not
fully understood. The results are, therefore, not
always satisfactory; but the alternative to applying
incompletely understood methodology is to deny a
patient a modality of diagnosis or therapy which
may be of substantial benefit. In the case of electronic monitoring of the fetus, an attempt is made
to intercept a pathological process before the more
clearly defined end points of irreversible damage
occur. That fact in itself raises the need for much
sharper criteria of jeopardy at a point of reversibility.
Labor imposes a period of temporary hazard,
the main component of which is related t9 a loss or
diminution of exchange across the placenta. (One
must also be mindful of the hazard to the fetus
which can be imposed by antenatal medication.)
Exchange across the placenta is adversely affected
by a variety of conditions:
1.

2.

3.

Obstetrical catastrophies such as abruptio
placentae, placenta previa, and uterine
rupture which usually cause disruption of
the intervillous space and sheering off of
a part or all of the placenta.
Hypotension and hypovolemia whether due
to compression of the vena cava, hemorrhage, or epidural anesthesia, reduce the
uterine blood flow.
Uterine hypertonus whether due to oxytocin stimulation, toxemia, or idiopathic
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results in a decreased net perfusion pressure of the placenta and a decreased
uterine diastole.
4. Mechanical interference with the umbilical
cord may occur either as a total event
with prolapse or, as is more commonly
found, with contractions. Surprisingly, intermittant cord compression may be well
tolerated, although it requires close vigilance and preparation for possible operative delivery.
5. Maternal vascular insufficiency such as
may be encountered with chronic hypertension, long standing diabetes, or toxemia, lowers the uterine blood flow and
hence, the availability of oxygen and nutrients to the fetus.
The methodology is as follows. Stress is measured by means of a pressure transducer connected to the amniotic sac by a fluid-filled catheter.
The response of the fetus is measured by means of
a heart rate meter which is driven by the FECG
signal obtained through an electrode attached to
the fetal scalp. These two parameters are measured and displayed by a Corometricst fetal monitor which was designed by Dr. Hon. The experience
at the Medical College of Virginia has demonstrated
this unit's reliability, which is a prime factor in
our choice of it. The electronic circuitry is digital
so that if the machine is working, it can be expected to give correct answers. Heart rate and
intra-amniotic pressure are simultaneously displayed,
and the chart patterns are used to predict compromise.
The development of more precise instrumentation for evaluating fetal heart rate patterns has
brought with it the necessity of inventing a more
precise vocabulary to describe the various aspects
demonstrated by the new methodology.
1. Bradycardia is a decrease in the baseline
of the heart rate.
2. Tachycardia is an increase in the baseline heart rate.
3. Acceleration is a periodic increase in the
fetal heart rate.
4. Deceleration is a periodic depression of
the heart rate.
5. Irregularity is a variation from the baseline heart rate and is characteristic of the
fetus who retains homeostatic mechanisms.
6. Period changes are the ones which are of
t Corometrics Medical Systems, Inc.

interest in predicting fetal jeopardy. The
periodicity is related to the uterine contraction.
Three patterns emerge from the extensive
work of Dr. Hon which could be correlated with
physiologic events. The first of these is called early
deceleration and is characterized by a deceleration
in the fetal heart rate which occurs with the onset of
uterine contraction. The change tends to mirror
the uterine pressure curve and may be abolished
by the use of atropine. This type of change implies
no alteration in the acid-base status and has a
good prognosis. It may, however, be quite marked
as will be demonstrated in Fig. 1. The second pattern is that of late deceleration, and it is associated
with utero-placental insufficiency. This type of deceleration has a late onset with respect to the
onset of the uterine contraction; in fact, the onset
of the deceleration is often at or beyond the
acme of the uterine contraction. It is frequently
associated with an elevated fetal heart rate and
may not fall below 100 beats per minute. This
type of deceleration is related to anoxia and
is connected with markedly depressed infants in
significantly high statistics. The ability to pick up
this type of deceleration is one of the distinctive
advantages of continuous electronic monitoring.
The third type of deceleration pattern is labeled
variable deceleration, and it is believed to be due
to compression of the umbilical cord. It is variable
with respect to the onset of the uterine contraction
and tends to be variable in shape. It may have
either a "fractured" configuration or a deep U-shape.
This pattern is the typical one leading to cesarean
section for fetal distress. Cord compression, while
it may have dire implications, is usually well tolerated, at least in the initial phases. The cord compression pattern appears also to be vagally mediated
and is susceptible to marked modification by the
use of atropine. At this point I would like to say
that when the cord is clamped at birth, physiologic
adjustments are required to compensate for that
part of the cardiac output which would normally go
to the placenta (about 50-60% of the fetal cardiac
output). These adjustments which take place about
the time of the first breath result in the alteration
of the fetal heart from the parallel arrangement
to a series configuration. This alteration cuts the
cardiac output in half, and incorporates the lung
as an organ through which all blood must pass.
Now let us look at some specific illustrations
of the various cord patterns and indicated therapy.
Figure 1 illustrates some of the problems of moni-
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Fig. I- Fetal heart rate tracing of early deceleration. There was no evidence of depression at birth.

taring the pressure from the abdomen as well as
demonstrating marked early deceleration due to
compression of the fetal ·heart. This tracing was
recorded with the father present in the labor room.
He had expressed a strong interest in having this
monitoring equipment used on his wife wheri she
was in labor. After application of the scalp electrode it was noted that there were falls to levels
of 80 beats per minute or less with every contraction. However, the acmes of both the deceleration
and the uterine contraction occurred approximately
simultaneously. Tqe prediction was that the baby
would show no evidence of depression, and such
was the case.
Figure 2 is that of a patient with Rh disease
who went into spontaneous labor at 35 weeks after
an amniocentesis-_ The fetal heart rate tracings
show marked deceleration with contractions which
are interpreted as the variable type due to cord
compression. Since this was a high-risk baby, I
would have had to deliver this patient by cesarean
section if I had not had the instrumentation to precisely monitor the fetus during her labor. In spite of
the fetal heart rate tracings, I was required to watch
the patient during a labor lasting l)everal hours,

following which she delivered a baby without evidence of depression. The normal delivery was best
for the mother and for the baby, but it was certainly harder on the physician.
Figure 3 shows an instance in which the physicians managing the patient did not understand
the significance of fetal heart rate tracing. This
episode occurred in our early experience at M.C.V.
In addition to marked late deceleration, frequent
premature contractions are also noted. This infant
died while preparations were being made for
cesarean section after the physicians had been
watching this pattern for a prolonged period of
time.
It should be pointed out that not every fetus
will observe the same degree of reserve, so that
some infants will exhibit utero-placental insufficiency with relatively mild uterine contractions,
whereas other fetuses will exhibit very little · response to even marked hypertonus.
Figure 4 is included to show a tracing which
was presented in one of our obstetrical conferences.
It is typical of the longer tracing which should
always be consulted for evidence of progression with
passage of time. The pattern is that of variable de-
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celeration with a rounding off of the shoulder of the
recovery phase. By following this pattern, we saw
that there was a prolongation of recovery most consistent with a progressive cord problem. The infant
delivered before evidence of anoxia appeared in the
chart, without evidence of depression. There was as
predicted, a tight cord around the neck.
While I feel that the technology required for
electronic monitoring of the fetus has reached a
degree of development adequate for clinical use, a
few words of caution seem to be in order.
1. The emotions of the obstetrician are
treated much more roughly than previously since he is committed to a vigilance
which may last several hours in contrast
to simply performing a cesarean section
which might or might not be of benefit
to the mother and fetus.
2. The instruments are only slightly more
fool-proof than the obstetricians using
them and do have weak links; for example, an integral part of the units utilized at M.C.V. is a Statham® strain

3.

4.

gauge. Over a period of 6 weeks, about
twelve hundred dollars' worth of these
strain gauges were rendered inoperable
by improper technique-an occurrence
that has not been unique to M.C.V.
Reading the tracings requires an active interest and practice which appears to
make it difficult to establish the technique in a new hospital unless someone
is there to instruct the obstetricians in
the technique and to act as a back-up
consultant.
External monitors and accessories to convert present monitoring units to external
monitoring are beginning to appear
which will increase acceptability of electronic monitoring. These instruments generally work on the Doppler principle
which is utilized in most well-known instruments such as the Doptone® to detect
the fetal heart. Though this type of instrumentation has been demonstrated
here, we have not seen any which we
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consider sufficiently reliable to consider
abandoning the use of the scalp electrode.
Probably, reliable external monitoring
equipment will become generally available
in the next two years.
5. The insertion of the amniotic catheter is
troublesome and requires some practice.
The catheter usually can be inserted and
does give accurate measurements of the
labor. Monitoring the labor from the abdomen is not as satisfactory. It gives only
a rough estimate of intensity and no indications of changes in baseline pressure.
6. The present reliable instrumentation requires rupture of the membranes, which
may not always be acceptable. Dilatation
of 3-4 cm is also required for easy application and insertion.
What are the benefits?
1. Treatment is made on a more exact diagnosis. It is very true that at this stage
the information extracted is relatively
crude and that the mechanisms of the
changes and their implications for longterm survival and function are only incompletely understood. But the presence
of compromise in labor is more accurately

2.

predicted than by other methods of assessment. Most of us will see this method
of evaluating the fetus become routine
for both high-risk and routine labors.
The use of electronic monitoring encourages the obstetrician to consider the
implications of labor to both the mother
and the fetus, rather than just as .a period
of time which must be passed before an
attempt is made to deliver a baby, at
whose condition we can only guess.

REFERENCES
CALDEYRO-BARCIA, R ., EscARCENA, L., GuuN, L., ARNT,
I. C ., AND MENDEZ-BAUER, C. Relationship between blood
pH and heart rate in the human fetus during labor. Am . J.
Obstet. Gynec. 97:4, 1967.
HoN, EDWARD H . The classification of fetal heart rate. I.
A working classification. Obstet. Gynecol. 22 : 137, 1963.
HoN, E. H. AND QUILLIGAN, E. J. The classification of fetal
heart rate. II. A revised working classification. Conn. Med.
31 :799, 1967.
HON, EDWARD H. AND KHAZIN, AIDA F. Observations on
fetal heart rate and fetal biochemistry. Am. J. Obstet.
Gynec. 105 : 5, 1969.

Femininity and Sexuality*
ALLAN C. BARNES, M.D.
Vice-President, Biomedical Sciences, Rockefeller Foundation,
New York, New York

In the second of the two McGuire Lectures, Dr.
Barnes discussed the nature of femininity and sexuality. He began by pointing out that people usually
turn first to the medical profession when seeking
help in solving their sexual problems. Though some
of these individuals may require psychiatric care,
most of them are simply misinformed and need to be
reeducated. "We [physicians] need to consider their
problems non-judgmentally and not let our own
particular attitudes and views intrude too much,"
said Dr. Barnes.
A contributing factor to this general misinformation about sexuality is the reluctance to acknowledge
that sexual intercourse is the most pleasurable physical act one can perform. Mothers rarely convey this
to their daughters when discussing sex with them,
and teenagers find it embarrassing. Recognizing
this, Dr. Barnes declared that he would devote most
of his talk to outlining a number of "true things"
about the enjoyability of sexual intercourse. Among
these are the facts that ( 1) it is the most pleasurable
act one can perform; (2) it is an act of bilateral enjoyability; and ( 3) this enjoyability is basic to heterosexual relationships. It is also true that the enjoyability of intercourse can be analyzed by dividing it
into sexual arousal and orgasm. Doctor Barnes then
went on to discuss the process of being aroused, its
physiological aspects in both the human male and
female, and the physiological nature of sexual
orgasm.
Another important "true thing" about the enjoyability of sex is that the pleasure is different in the
male and female. This difference in the mental component versus the physical, tactile component in
each gender interests Dr. Barnes most. For the male,
the process of becoming aroused is overwhelmingly
mental. Once he is aroused, it becomes physical.

* Summary of the second McGuire Lecture presented
on December 3, 1971, at the Medical College of Virginia,
Richmond. Doctor Barnes did not wish to have his speech
published in its entirety.
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With the female, almost the exact opposite is the
case. "Becoming sexually aroused is a matter of
being embraced, . . . stroked, . . . kissed, . . .
caressed, finding erogenous zones. . . . As soon as
[arousal] is achieved, the process becomes predominantly mental.
"But," continued Dr. Barnes, "there is another
phenomenon that takes place [which] we ... lump
as appetite.. . . Appetite is [the] desire for sexual
contacts . . . that might arouse . . . or that might
lead on to orgasm. For the male .. . it is probably
correct to use the word 'hunger' because hunger actually has associated with it physical and chemical
changes, and in the male . . . the urge to [have]
intercourse in the absence of being aroused is based
upon the fullness and tension in the seminal vesicles."
In the female, this urge is true appetite, defined as
being the memory of something that makes one feel
pleasant or happy. Through the years the female's
appetite for sex increases while the male's decreases,
and such divergence in needs requires compromise
and adjustment in both partners.
One of the most important "true things" about
the enjoyability of sexual intercourse, and the one
which usually brings the patient into the physician's
office, is that it may be lost or it may never have been
achieved. Doctor Barnes feels that· there are a
variety of ways in which this could occur. The stimulus that is applied is either wrong or inappropriate.
For example, too often young people who are going
to school while they are trying to hold down a job,
or keep up the housework, relegate an act that is
basic to their marriage to that part of the day when
they are too tired to do anything else. Loss of sexual
pleasure may be due to "poor male technique." This
is related to the assumption in our society that the
male is automatically an expert in lovemaking and
that any instruction from the female lowers his
status. Or there is the behavior factor. "Behavior as
we think we are expected to behave . .. accounts for
much of what passes as husband and wife love," says
Dr. Barnes. It also accounts for the reason why a
75
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woman may lose her enjoyment of sex at the time
she has a baby or after a hysterectomy.
Or sexual enjoyment may never be achieved at
all. In our society we seem to worship simultaneous
orgasm, but Dr. Barnes believes that our real obligation is ". . . for each partner to make sure the other
is satisfied." He also feels that, contrary to the
popular theory put forth in the manuals on sexual
technique, the man should "go slow," " ... the ...
fundamental woman's obligation in sexuality is to go
fast."
Doctor Barnes then addressed himself to those
people under thirty as potential parents: "The loss
of the enjoyability of [sexual] intercourse is less
common today than it ever was before .... But in
your children we can take another great step forward
if we can, in truth, raise them to accept their sex-
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uality without difficulty, without embarressment,
without hangups. But I make four suggestions: First
... will you be not too fixed or rigid in the definition
of femininity you hold out before [your daughter]. ...
this is a society that puts a woman somewhat at a
disadvantage, and she is adjusting to this role, she
is feeling insecure . . . . Second . . . remember that
you owe us the obligation of pushing [sex education]
on back into the grade schools and into kindergarten.
... Third ... find your reasons for the standards you
maintain and announce them. But don't leave the
implication that [sex] is an unpleasant or a bad
act. ... Fourth ... raise your daughters with a positive pride in their femininity. It is a wonderful thing
to be a woman. Make sure your daughter knows
that."
MCV/Q STAFF

Venereal Disease*
ROBERT E. PETRES, M.D.
Instructor of Obstetrics and Gynecology,
Medical College of Virginia, Richmond, Virginia

Venereal disease, as we define it, is any disease
that is propagated or transmitted by sexual intercourse. Traditionally we have taught medical students that this included chancroid, lymphogranuloma
venereum, granuloma inguinale, gonorrhea, and
syphilis. Then we taught them enough to be able to
match up Donovan bodies, Frei test, Thayer Martin
media, and at that point we felt that we had pretty
much done our job. If we are to stick to the criteria
of diagnosis, I suggest we should also consider as
venereal diseases, Trichomonas, incomplete abortions, septic abortions, ectopic pregnancy, unwanted
pregnancy, crab lice, herpes simplex virus (type 2),
and carcinoma of the cervix. There is considerable
disparity among these conditions, but they all have
one thing in common: they reflect sexual activity.
Trichomonas, on the one hand, may represent sexual
activity several years in the past. The trichomonad
may lie asymptomatic in the female vagina or the
male urethra only to become apparent weeks, months,
or even years later. Squamous cell carcinoma, on the
other hand, is more like a scoreboard of total sexual
activity. Early intercourse, multiple partners, multiple pregnancies are all contributing factors in the
development of carcinoma of the cervix. Cervicitis
may lie somewhere in between these two extremes
and indeed be somewhat related to both.
Currently, gonorrhea is enjoying the most popularity, both in the literature and in the population.
We are unquestionably in the midst of an epidemic.
Last year in the United States, there were probably
two million cases of acute gonorrhea. We developed
forty thousand cases a week. One person gets gonorrhea every 15 seconds; every week sixty-five boys
returning from Viet Nam have the disease. Most of
these are under treatment. More than 25 % of patients with gonorrhea are less than 20 years of age;
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more than 50% of patients with gonorrhea are less
than 29 years of age. We are finding that the incidence in the general population is much higher
than previously supposed. Screening in OB and
GYN clinics across the country have consistently
come up with figures of between 5 and 10 percent
incidence of gonorrhea in those screened. It can be
safely said that one out of every ten girls between
the ages of 15 and 25 years of age harbors the
gonococcus.
The fact that we have had asymptomatic female carriers has been known for sometime. As a
matter of fact, probably 75% to 80% of women
with gonorrhea are totally asymptomatic. But they
are still infectious. They can still spread the disease.
We are just lately finding, much to our consternation, that there are asymptomatic male carriers as
well.
In the city of Norfolk, the Public Health Department made a series of studies on male contacts
of known female patients with gonorrhea. The result
was a raw incidence of 12% positive cultures in
asymptomatic men. If you corrected this by ruling
out the patients from whom cultures had been taken
during the incubation period, you would still have a
figure of 6%. In one uncontrolled and unpublished
series that was performed here by our Health
Department, they found 22 positive cultures in
asymptomatic men out of a group of 144 male contacts. I hasten to add that these 22 were not separated out as to whether or not they were in the
incubation period. With this large number of
asymptomatic patients in both the male and female
patient population, the obviously pressing problems
are to discover an adequate method of diagnosis
and to treat these people.
The first culture technique for the diagnosis
of gonorrhea was the use of chocolate agar. This
is plated with pus from the urethra, or the cervix,
or the anus, and then incubated under 10% of C02
at 37°C. With this classic type of culturing, sub77
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culturing must be carried out as well as sugar fermentations. It is frequently ten days before the
diagnosis can be made. Overgrowth is a problem,
particularly with proteus; since it may obliterate the
gonococcal culture.
The next improvement in diagnostic method
was the development of Thayer Martin media.
This media initially was chocolate agar with the addition of antibiotics, ristocetin, and polymixin. Lately
it is referred to as the VCN plate which contains
Vancomycin®, colistin, and nystatin for the suppression of the non-pathogenic bacteria and other contaminates such as staph, strep, and the gram negatives.
Thayer Martin media obviously has its advantages, but its chief disadvantage is that in order to
be effective it should be plated directly from the
patient, and as a result, the specimen frequently
loses viability on the way to the lab. Thayer Martin
media also has one small drawback due to its inhibitive factor, so that in terms of speed, the gonococcus may take up to three days to grow out,
whereas on chocolate agar it will frequently grow
out in 24 hours.
Carrying media prepared by Stuart is a liquid
in which the specimen can be immersed and shipped
to the lab. It is a non-nutrient media, and some cultures are lost because of this, but it has the advantage of protecting the gonococcus from oxidation.
Transgro has recently been developed. This is
a combination of a selective gonococcal media that
is also a transport media. It is a modified Thayer
Martin type media. It differs from the others in that
it is put up in a one-ounce medicine bottle with a
narrow neck. The media is layered on the side that
it forms a flat plate on the inside of the bottle
much like a blood culture bottle. Transgro contains
an increased amount of agar to make the culture
media more rigid for mailing, and it contains a higher
concentration of sugar. The bottle has an atmosphere
of 10% C02 under a rubber screw tip. It can be
plated directly from the patient at the time of examination and held at room temperature until ready
for mailing. It appears to be a very good media for
office practice; however, I would use with caution
any new technique, as laboratories will need time to
get used to it.
In addition to culturing methods for diagnosing
gonorrhea, the fluorescent antibody techniques have
been developed. The direct method is done by
plating the specimen on a glass slide, overlaying it
with fluorescent antibody, and then looking at it
under an ultraviolet microscope. The gonococcus
will fluoresce. Unfortunately, this will not reproduce
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the results obtainable with ordinary culture. It is
fast but its effectiveness is only in the range of 60%.
The delayed fluorescent antibody technique is much
better. It is done by first plating a chocolate agar
slant, allowing the specimen to grow on the slant
for 18 hours, and then removing the specimen to a
slide. During this time, the gonococcus will multiply
in such numbers that when it is visualized under an
ultraviolet light microscope one has a much higher
incidence of positive results. Thayer Martin media,
Transgro, chocolate agar, and the delayed fluorescent
antibody technique all have fairly comparable results of being positive in 75 % to 80% of known cases.
Who should be cultured? I think that we should
culture all prenatal patients because the incidence
of gonorrheal ophthalmia in newborns is on the rise.
In addition to prenatal patients, I am beginning to
believe that we should also culture for gonorrhea
everyone who is given a pack of birth control pills;
the reason being that anyone needing contraception
is obviously sexually active. And we should focus
particular attention on the 15- to 25-year-olds seeking
contraceptives, as they are the most susceptible
group.
Gonorrhea is a serious medical problem. Too
frequently we think of it as being a nuisance, but
it is more than that. Eighty percent of women are
asymptomatic, but we must remember that 10%
will develop salpingitis, and 3 % will be forever
sterile from the disease. The largest cause of infertility in our patient population is unquestionably
gonorrhea.
The treatment of choice remains penicillin, for
the time being anyway. The minimum treatment
for the female is 4.8 million units of procaine penicillin. I might interject here that in our practice,
we have hospitalized all patients suspected of having
salpingitis or those with systemic symptoms and
treated them with high levels of aqueous penicillin,
in addition to procaine penicillin. For years, much
more modest doses of the drug gave good cure
rates. I think the initial recommended dose of penicillin for gonorrhea by the Public Health Department was something like a single shot of 40
thousand units. Now, I am advocating 4.8 million
units because of the biologic change in the gonococcus. In 1947, the minimum lethal concentration
of penicillin was 0.004 units/ ml; in 1957, 0.1
units/ ml; in 1967, 1.0 units/ ml. This indicates a two
hundred and fifty-fold decrease in the sensitivity of
the gonococcus to penicillin. You can see by this
trend that the time is coming when we can no longer
use penicillin, because the capacity of the female
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buttock to receive procaine penicillin has been
reached. Much of the current emphasis in research
is on developing antibiotic alternatives for penicillin.
Tetracycline is usually considered a second-line
drug. Good results have also been achieved with
kanamycin, chloramphenicol, and erythromycin. The
combination of ampicillin and probenecid has
been used with success, and I might add that probenecid, which decreases excretion of penicillin,
may well be advised with the use of procaine penicillin. There is one study in Greenland using a combination of 5 million units of procaine penicillin and
one gram of probenecid. With this they have shown
that they are able to arrest the decreasing sensitivity of the gonococcus to penicillin.
Benzathine penicillin should never be used to
treat gonorrhea. A series of patients given 1.2 million units of benzathine penicillin were checked
24 hours later for circulating penicillin. More than
50% had less than 0.1 unitjml which is ten times
less than the amount necessary to treat gonorrhea,
and this may in fact have lead to the desensitization
of the disease to the drug.
If gonorrhea is the prima donna of venereal diseases, the spectre lurking in the shadows is syphilis.
We are not currently seeing a surge in the incidence
of syphilis; however, last year the total number of
cases did rise slightly although the rate of new cases
did not. Three hundred babies born last year had
congenital syphilis. Consider three hundred babies
with smallpox, syphilis being the great pox. Two
thousand people died last year of syphilis. There are
five hundred thousand patients in this country with
latent syphilis untreated or undertreated today. That
syphilis is not showing the same current increase as
gonorrhea is attributed by many to the fact that
syphilis may be aborted by the treatment of gonorrhea. One series has attempted to prove that the
current recommended dosage of procaine penicillin
will abort an incubating syphilis infection. This
series, begun in 1957, utilized as its criteria for
the cure of syphilis, the fact that the patients were
sero-negative and had no lesion of syphilis after
three months. I think that we should be a bit cautious about predicting whether or not these patients
are going to develop latent syphilis, and there are
physiologic reasons for having doubts. We know
that we can recover the spirochete from the anterior
chamber of the eye and from the cerebrospinal
fluid, and we also know that it is extremely difficult
to get therapeutic levels of penicillin into these
body fluids. A second physiologic fact that makes
me question this evidence . rs that penicillin
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will kill a spirochete only when the spirochete is
replicating. It replicates every 32 hours, but we can
assume that every spirochete is not killed the first
time. Procaine lasts 72 hours with good levels, so
the use of relatively short-acting penicillin like procaine as opposed to the long-acting benzathine leaves
one to wonder if all these syphilis infections are
cured or if the presenting symptoms are merely delayed or aborted altogether with the possibility of
latent syphilis developing.
There has been much speculation, but little
has been proven, about the increase in the incidence of venereal disease. It is very easy to say,
"Well, more people are doing more things more
often than they have been in the past." But it is
extremely difficult to prove. There is data to support this. Kinsey, in the 1940's, found that 20 %
of 20-year-old college women had had premarital
intercourse. Vance Packard in the 1960's found that
43 % of 20-year-old college females had had premarital intercourse. This increase shows, if it continues along these lines, that 60% of women born
this year will have had premarital intercourse by the
time they reach 20 years of age. And these are college women. If we add all women, we may well say
90% of women 20 years old will have had premarital intf"·.course. Now it is quite true that people
from high er socio-economic and educational levels
have more varied and imaginative sexual lives; however, people from lower socio-economic levels invariably start sooner. The incidence of gonorrhea in
the younger age group is high; but not higher now
than six years ago. I think that we continue to fool
ourselves. We look at the incidence of gonorrhea
as we say, "My goodness, twenty-five percent of the
patients with gonorrhea are under twenty years of
age," and then we forget about it. We come back
five years later and say, "My goodness, what are
these girls doing!"
Two days ago, the Richmond city newspapers
reported that 8 % of the girls at a local high school
are pregnant, and everyone looked at this with
amazement. Well, 8% of those girls have been pregnant for a long time. Seniors in high school are
sexually mature girls. I think we must accept
these facts . Once a girl has had intercourse for the
first time, be it at 14, 15, 16, or 18, she is not
going to revert.
Some people blame the current surge in the incidence of gonorrhea on birth control pills. They
say that when the condom was used there was a
lesser incidence. This is extremely difficult to prove;
I haven't seen any condom companies going out
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of business lately. It amazes me that a fair number
of adolescent women get birth control pills primarily because they don't want to get pregnant.
They would not, however, even consider carrying
condoms for the same protection. Condoms have
some effect in decreasing the spread of gonorrhea,
but would you be happy to rest back on condoms
for birth control? No one has been, so why should
you be satisfied with a condom as a means of controlling the spread of gonorrhea.
There is a current interest in antibiotic vaginal
cream. I have a great deal of trepidation about any
medication that is antibiotic and therefore antigenic
in nature that is persistently rubbed on a mucous
membrane. I think this would be an excellent way to
sensitize half the population of the country.
The limitations of public education must be
realized. The basic idea of alerting the public to the
inherent dangers of sexual contact is of academic
interest but hardly practical as policy. The increasing sales of tobacco should reinforce that point. It
may be of value to disseminate information about
the signs and symptoms of venereal disease because
it is likely to bring infected patients to medical attention, hopefully before they spread the disease.
This is particularly applicable to syphilis because it
has a long incubation period during which the patient is noninfectious and may be cured before
spreading the disease. Gonorrhea's short incubation
period, 4-10 days, makes it difficult for the physician
to get to the patient prior to the further spread of
the disease even under the best of circumstances.
At this point in time, the most intensive efforts
toward education should be made in the medical
schools. Very shortly these students will be faced
with large numbers of patients with venereal disease,
and we must prepare them. Unfortunately, this area
in the medical school curriculum has been progressively crowded out by what seemed more important.
It is now apparent that even though the prevalence
of venereal diseases may wax and wane, they will
always represent a sizable medical problem. We
must gear medical education and medical reeducation to meet these needs.
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